Active return system

Information

  • Patent Grant
  • 8791656
  • Patent Number
    8,791,656
  • Date Filed
    Friday, May 31, 2013
    11 years ago
  • Date Issued
    Tuesday, July 29, 2014
    10 years ago
Abstract
An example particle accelerator includes a magnet to generate a magnetic field, where the magnet includes first superconducting coils to pass current in a first direction to thereby generate the first magnetic field, and where the first magnetic field is at least 4 Tesla (T). The example particle accelerator also includes an active return system including second superconducting coils. Each of the second superconducting coils surrounds, and is concentric with, a corresponding first superconducting coil. The second superconducting coils are for passing current in a second direction that is opposite to the first direction to thereby generate a second magnetic field having a magnetic field of at least 2.5 T. The second magnetic field has a polarity that is opposite to a polarity of the first magnetic field.
Description
TECHNICAL FIELD

This disclosure relates generally to an active return system for a superconducting magnet.


BACKGROUND

Particle therapy systems use an accelerator to generate a particle beam for treating afflictions, such as tumors. In operation, particles are accelerated in orbits inside a cavity in the presence of a magnetic field, and removed from the cavity through an extraction channel. The particles are part of a beam, which is applied to the patient for treatment. The magnetic field is generated by a magnet, which produces magnetic flux. Too much stray magnetic flux can adversely affect the operation of the accelerator and of other components of the particle therapy system. A return may therefore be used to route the stray magnetic flux. Ferromagnetic returns can be heavy, and add considerable weight to the accelerator. This can be problematic in some cases.


SUMMARY

An example particle accelerator comprises a magnet to generate a magnetic field, where the magnet comprises first superconducting coils to pass current in a first direction to thereby generate the first magnetic field, and where the first magnetic field is at least 4 Tesla (T). The example particle accelerator also comprises an active return system including second superconducting coils. Each of the second superconducting coils surrounds, and is concentric with, a corresponding first superconducting coil. The second superconducting coils are for passing current in a second direction that is opposite to the first direction to thereby generate a second magnetic field having a magnetic field of at least 2.5 T. The second magnetic field has a polarity that is opposite to a polarity of the first magnetic field. The example particle accelerator may include one or more of the following features, either alone or in combination.


A power supply may provide current to both the first superconducting coils and the second superconducting coils. The first superconducting coils and the second superconducting coils may be mounted on a structure. The structure may comprise at least one of stainless steel and carbon fiber.


The first superconducting coils may be mounted on an interior of the structure and the second superconducting coils may be mounted on an exterior of the structure such that the second superconducting coils are separated from the first superconducting coils by at least part of the structure. A banding ring may be around the second superconducting coils.


Magnetic pole pieces may define the cavity, and the structure may be around at least part of the magnetic pole pieces. A cryostat cover may be around at least part of the structure and at least part of the magnetic pole pieces. The cryostat cover may comprise a non-ferromagnetic material.


The particle accelerator may weigh less than 15 tons, less than 10 tons, less than 9 tons, less than 8 tons, less than 7 tons, and so forth.


A proton therapy system may comprise the foregoing particle accelerator (and variations thereof), along with a gantry on which the particle accelerator is mounted. The gantry is rotatable relative to a patient position. Protons are output essentially directly from the particle accelerator to the patient position. The particle accelerator may be a synchrocyclotron. The proton therapy system may also comprise a particle source to provide ionized plasma to a cavity containing the first magnetic field and a voltage source to provide voltage to accelerate a beam comprised of pulses of ionized plasma towards an exit.


An example particle accelerator may comprise a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles to produce a particle beam, where the cavity has a first magnetic field for causing particles accelerated from the plasma column to move orbitally within the cavity, and where the RF voltage is controllable to vary in time as the particle beam increases in distance from the plasma column. The example particle accelerator may also comprise a magnet to generate the first magnetic field in the cavity, where the magnet comprises first superconducting coils to pass current in a first direction to thereby generate the first magnetic field. The example particle accelerator may also comprise an active return system comprising second superconducting coils, where each of the second superconducting coils surrounds, and is concentric with, a corresponding first superconducting coil. The second superconducting coils are for passing current in a second direction that is opposite to the first direction to thereby generate a second magnetic field having a magnetic field of at least 2.5 Tesla (T). The second magnetic field has a polarity that is opposite to a polarity of the first magnetic field. The example particle accelerator may include one or more of the following features, either alone or in combination.


The first magnetic field may be least 4 T. The second magnetic field may be at between 2.5 T and 12 T. The first magnetic field may be between 4 T and 20 T and the second magnetic field may be between 2.5 T and 12 T.


A single power supply may be used to provide current to both the first superconducting coils and to the second superconducting coils. The first superconducting coils and the second superconducting coils may be mounted on a structure. The structure may comprise at least one of stainless steel and carbon fiber. The first superconducting coils may be mounted on an interior of the structure and the second superconducting coils may be mounted on an exterior of the structure such that the second superconducting coils are separated from the first superconducting coils by at least part of the structure. A banding ring may be around the second superconducting coils.


Magnetic pole pieces may define the cavity, and the structure may be around at least part of the magnetic pole pieces. A cryostat cover may be around at least part of the structure and at least part of the magnetic pole pieces. The cryostat cover may comprise a non-ferromagnetic material.


The particle accelerator may weigh less than 15 tons, less than 10 tons, less than 9 tons, less than 8 tons, less than 7 tons, and so forth.


A proton therapy system may comprise the foregoing particle accelerator (and variations thereof), along with a gantry on which the particle accelerator is mounted. The gantry is rotatable relative to a patient position. Protons are output essentially directly from the particle accelerator to the patient position. The particle accelerator may be a synchrocyclotron. The proton therapy system may also comprise a particle source to provide ionized plasma to a cavity containing the first magnetic field and a voltage source to provide voltage to accelerate a beam comprised of pulses of ionized plasma towards an exit.


Two or more of the features described in this disclosure, including those described in this summary section, may be combined to form implementations not specifically described herein.


Control of the various systems described herein, or portions thereof, may be implemented via a computer program product that includes instructions that are stored on one or more non-transitory machine-readable storage media, and that are executable on one or more processing devices. The systems described herein, or portions thereof, may be implemented as an apparatus, method, or electronic system that may include one or more processing devices and memory to store executable instructions to implement control of the stated functions.


The details of one or more implementations are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.





DESCRIPTION OF THE DRAWINGS


FIG. 1 is a side cut-away view of a superconducting magnet.



FIG. 2 is top view of example main and active return coils.



FIG. 3 is a front view of an example particle therapy system.



FIG. 4 is a perspective, cut-away view of example components of a superconducting magnet with active return coils.



FIG. 5 is a front, cut-away view of example components of a superconducting magnet with active return coils.



FIG. 6 is a cross-sectional view of part of an example support structure and example superconducting coil windings.



FIG. 7 is a cross-sectional view of an example cable-in-channel composite conductor.



FIG. 8 is a cross-sectional view of an example ion source.



FIG. 9 is a perspective view of an example dee plate and dummy dee.



FIG. 10 is a perspective view of an example vault containing an example gantry and particle accelerator.





Like reference symbols in the various drawings indicate like elements.


DETAILED DESCRIPTION

Described herein is an example of a particle accelerator for use in a system, such as a proton or ion therapy system. The example particle therapy system includes a particle accelerator—in this example, a synchrocyclotron—mounted on a gantry. The gantry enables the accelerator to be rotated around a patient position, as explained in more detail below. In some implementations, the gantry is steel and has two legs mounted for rotation on two respective bearings that lie on opposite sides of a patient. The particle accelerator is supported by a steel truss that is long enough to span a treatment area in which the patient lies and that is attached at both ends to the rotating legs of the gantry. As a result of rotation of the gantry around the patient, the particle accelerator also rotates.


In an example implementation, the particle accelerator (e.g., the synchrocyclotron) includes a cryostat that holds a superconducting coil for conducting a current that generates a magnetic field (B). In this example, the cryostat uses liquid helium (He) to maintain the coil at superconducting temperatures, e.g., 4° Kelvin (K). Magnetic pole pieces are located inside the cryostat, and define a cavity in which particles are accelerated.


In this example implementation, the particle accelerator includes a particle source (e.g., a Penning Ion Gauge—PIG source) to provide a plasma column to the cavity. Hydrogen gas is ionized to produce the plasma column. A voltage source provides a radio frequency (RF) voltage to the cavity to accelerate particles from the plasma column. As noted, in this example, the particle accelerator is a synchrocyclotron. Accordingly, the RF voltage is swept across a range of frequencies to account for relativistic effects on the particles (e.g., increasing particle mass) when accelerating particles from the column. The magnetic field produced by running current through the superconducting coil causes particles accelerated from the plasma column to accelerate orbitally within the cavity.


A magnetic field regenerator (“regenerator”) is positioned near the outside of the cavity (e.g., at an interior edge thereof) to adjust the existing magnetic field inside the cavity to thereby change locations (e.g., the pitch and angle) of successive orbits of the particles accelerated from the plasma column so that, eventually, the particles output to an extraction channel that passes through the cryostat. The regenerator may increase the magnetic field at a point in the cavity (e.g., it may produce a magnetic field “bump” at an area of the cavity), thereby causing each successive orbit of particles at that point to precess outwardly toward the entry point of the extraction channel until it reaches the extraction channel. The extraction channel receives particles accelerated from the plasma column and outputs the received particles from the cavity as a particle beam.


The superconducting coil can produce relatively high magnetic fields. Traditionally, large ferromagnetic magnetic yokes acted as a return for stray magnetic field produced by the superconducting coil. For example, in some implementations, the superconducting magnet can generate a relatively high magnetic field of, e.g., 4 Tesla (T) or more, resulting in considerable stray magnetic fields. In some systems, such as that shown in FIG. 1, relatively large ferromagnetic return yokes 100 were used as a return for the magnetic field generated by superconducting coils 102. A magnetic shield 104 surrounded the pole pieces. The return yokes and the shield together dissipated stray magnetic field, thereby reducing the possibility that stray magnetic fields would adversely affect the operation of the accelerator. Drawbacks of this configuration may include size and weight. For example, in some such systems, the accelerator could have a weight on the order of 25 tons or more with correspondingly large dimensions.


In some implementations, therefore, the relatively large yokes and shield used because of the relatively high magnetic field may be replaced by an active return system. An example active return system includes one or more active return coils that conduct current in a direction opposite to current through the main superconducting coils. In some example implementations, there is an active return coil for each superconducting coil, e.g., two active return coils—one for each superconducting coil (referred to as a “main” coil). Each active return coil may also be a superconducting coil that surrounds the outside of a corresponding main superconducting coil. For example, a main coil 200 and an active return coil 201 may be arranged concentrically, as shown in FIG. 2.


Current passes through the active return coils in a direction that is opposite to the direction of current passing through the main coils. The current passing through the active return coils thus generates a magnetic field that is opposite in polarity to the magnetic field generated by the main coils. As a result, the magnetic field generated by an active return coil is able to dissipate the relatively strong stray magnetic field resulting from the corresponding main coil. In some implementations, each active return may be used to generate a magnetic field of between 2.5 T and 12 T or more. For example, an active return coil may be used to generate magnetic fields at, or that exceed, one or more of the following magnitudes: 2.5 T, 2.6 T, 2.7 T, 2.8 T, 2.9 T, 3.0 T, 3.1 T, 3.2 T, 3.3 T, 3.4 T, 3.5 T, 3.6 T, 3.7 T, 3.8 T, 3.9 T, 4.0 T, 4.1 T, 4.2 T, 4.3 T, 4.4 T, 4.5 T, 4.6 T, 4.7 T, 4.8 T, 4.9 T, 5.0 T, 5.1 T, 5.2 T, 5.3 T, 5.4 T, 5.5 T, 5.6 T, 5.7 T, 5.8 T, 5.9 T, 6.0 T, 6.1 T, 6.2 T, 6.3 T, 6.4 T, 6.5 T, 6.6 T, 6.7 T, 6.8 T, 6.9 T, 7.0 T, 7.1 T, 7.2 T, 7.3 T, 7.4 T, 7.5, 7.6 T, 7.7 T, 7.8 T, 7.9 T, 8.0 T, 8.1 T, 8.2 T, 8.3 T, 8.4 T, 8.5, 8.6 T, 8.7 T, 8.8 T, 8.9 T, 9.0 T, 9.1 T, 9.2 T, 9.3 T, 9.4 T, 9.5, 9.6 T, 9.7 T, 9.8 T, 9.9 T, 10.0 T, 10.1 T, 10.2 T, 10.3 T, 10.4 T, 10.5, 10.6 T, 10.7 T, 10.8 T, 10.9 T, 11.0 T, 11.1 T, 11.2 T, 11.3 T, 11.4 T, 11.5, 11.6 T, 11.7 T, 11.8 T, 11.9 T, 12.0 T, 12.1 T, 12.2 T, 12.3 T, 12.4 T, 12.5, or more. Furthermore, an active return coil may be used to generate magnetic fields that are within the range of 2.5 T to 12 T (or more) that are not specifically listed above.


The magnetic field generated by a main coil that may be within a range of 4 T to 20 T or more. For example, a main coil may be used to generate magnetic fields at, or that exceed, one or more of the following magnitudes: 4.0 T, 4.1 T, 4.2 T, 4.3 T, 4.4 T, 4.5 T, 4.6 T, 4.7 T, 4.8 T, 4.9 T, 5.0 T, 5.1 T, 5.2 T, 5.3 T, 5.4 T, 5.5 T, 5.6 T, 5.7 T, 5.8 T, 5.9 T, 6.0 T, 6.1 T, 6.2 T, 6.3 T, 6.4 T, 6.5 T, 6.6 T, 6.7 T, 6.8 T, 6.9 T, 7.0 T, 7.1 T, 7.2 T, 7.3 T, 7.4 T, 7.5 T, 7.6 T, 7.7 T, 7.8 T, 7.9 T, 8.0 T, 8.1 T, 8.2 T, 8.3 T, 8.4 T, 8.5 T, 8.6 T, 8.7 T, 8.8 T, 8.9 T, 9.0 T, 9.1 T, 9.2 T, 9.3 T, 9.4 T, 9.5 T, 9.6 T, 9.7 T, 9.8 T, 9.9 T, 10.0 T, 10.1 T, 10.2 T, 10.3 T, 10.4 T, 10.5 T, 10.6 T, 10.7 T, 10.8 T, 10.9 T, 11.0 T, 11.1 T, 11.2 T, 11.3 T, 11.4 T, 11.5 T, 11.6 T, 11.7 T, 11.8 T, 11.9 T, 12.0 T, 12.1 T, 12.2 T, 12.3 T, 12.4 T, 12.5 T, 12.6 T, 12.7 T, 12.8 T, 12.9 T, 13.0 T, 13.1 T, 13.2 T, 13.3 T, 13.4 T, 13.5 T, 13.6 T, 13.7 T, 13.8 T, 13.9 T, 14.0 T, 14.1 T, 14.2 T, 14.3 T, 14.4 T, 14.5 T, 14.6 T, 14.7 T, 14.8 T, 14.9 T, 15.0 T, 15.1 T, 15.2 T, 15.3 T, 15.4 T, 15.5 T, 15.6 T, 15.7 T, 15.8 T, 15.9 T, 16.0 T, 16.1 T, 16.2 T, 16.3 T, 16.4 T, 16.5 T, 16.6 T, 16.7 T, 16.8 T, 16.9 T, 17.0 T, 17.1 T, 17.2 T, 17.3 T, 17.4 T, 17.5 T, 17.6 T, 17.7 T, 17.8 T, 17.9 T, 18.0 T, 18.1 T, 18.2 T, 18.3 T, 18.4 T, 18.5 T, 18.6 T, 18.7 T, 18.8 T, 18.9 T, 19.0 T, 19.1 T, 19.2 T, 19.3 T, 19.4 T, 19.5 T, 19.6 T, 19.7 T, 19.8 T, 19.9 T, 20.0 T, 20.1 T, 20.2 T, 20.3 T, 20.4 T, 20.5 T, 20.6 T, 20.7 T, 20.8 T, 20.9 T, or more. Furthermore, a main coil may be used to generate magnetic fields that are within the range of 4 T to 20 T (or more) that are not specifically listed above. In some implementations, the currents through the active return coils and the main coils have the same (or about the same (e.g., within 10% difference)) magnitude. In some implementations, the currents through the active return coils and the main coils have different magnitudes.


In some implementations, each main coil is superconducting and made of niobium-3 tin (Nb3Sn) and each active return coil is superconducting and made of niobium-titanium. However, in other implementations, each main coil and each return coil may be made of the same, different, and/or other materials than those noted above.


In some implementations, the same (e.g., a single) power supply may be used to generate current for both the main coil(s) in the magnet and the active return coil(s). This enables the current through all coils to ramp appropriately, and may be useful in example particle therapy systems.


The active return system described herein may be used in a single particle accelerator, and any two or more of the features thereof described herein may be combined in a single particle accelerator. The particle accelerator may be used in any type of medical or non-medical application. An example of a particle therapy system in which a superconducting magnet having the active return system described herein may be used is provided below.


Referring to FIG. 3, a charged particle radiation therapy system 300 includes a beam-producing particle accelerator 302 having a weight and size small enough to permit it to be mounted on a rotating gantry 304 with its output directed straight (that is, essentially directly) from the accelerator housing toward a patient 306. In some implementations, the weight of the particle accelerator may be less than, or about equal to, one of the following weights: 20 tons, 19 tons, 18 tons, 17 tons, 16 tons, 15 tons, 14 tons, 14 tons, 13 tons, 12 tons, 11 tons, 10 tons, 9 tons, 8 tons, 7 tons, 6 tons, 5 tons, or 4 tons. However, the particle accelerator may have any appropriate weight.


In some implementations, the steel gantry has two legs 308, 310 mounted for rotation on two respective bearings 312, 314 that lie on opposite sides of the patient. The accelerator is supported by a steel truss 316 that is long enough to span a treatment area 318 in which the patient lies (e.g., twice as long as a tall person, to permit the person to be rotated fully within the space with any desired target area of the patient remaining in the line of the beam) and is attached stably at both ends to the rotating legs of the gantry.


In some examples, the rotation of the gantry is limited to a range 320 of less than 360 degrees, e.g., about 180 degrees, to permit a floor 322 to extend from a wall of the vault 324 that houses the therapy system into the patient treatment area. The limited rotation range of the gantry also reduces the required thickness of some of the walls (which are not directly aligned with the beam, e.g., wall 330), which provide radiation shielding of people outside the treatment area. A range of 180 degrees of gantry rotation is enough to cover all treatment approach angles, but providing a larger range of travel can be useful. For example the range of rotation may be between 180 and 330 degrees and still provide clearance for the therapy floor space. Angles of rotation other than these may be used.


The horizontal rotational axis 332 of the gantry may be located nominally one meter above the floor where the patient and therapist interact with the therapy system. This floor may be positioned about three meters above the bottom floor of the therapy system shielded vault. The accelerator can swing under the raised floor for delivery of treatment beams from below the rotational axis. The patient couch moves and rotates in a substantially horizontal plane parallel to the rotational axis of the gantry. The couch can rotate through a range 334 of about 270 degrees in the horizontal plane with this configuration. This combination of gantry and patient rotational ranges and degrees of freedom allow the therapist to select virtually any approach angle for the beam. If needed, the patient can be placed on the couch in the opposite orientation and then all possible angles can be used.


In some implementations, the accelerator uses a synchrocyclotron configuration having a very high magnetic field superconducting electromagnetic structure. Because the bend radius of a charged particle of a given kinetic energy is reduced in direct proportion to an increase in the magnetic field applied to it, the very high magnetic field superconducting magnetic structure permits the accelerator to be made smaller and lighter. The synchrocyclotron uses a magnetic field that is uniform in rotation angle and falls off in strength with increasing radius. Such a field shape can be achieved regardless of the magnitude of the magnetic field, so in theory there is no upper limit to the magnetic field strength (and therefore the resulting particle energy at a fixed radius) that can be used in a synchrocyclotron.


In the example implementation shown in FIG. 3, the superconducting synchrocyclotron 302 operates with a peak magnetic field in a pole gap of the synchrocyclotron of 8.8 Tesla. The synchrocyclotron produces a beam of protons having an energy of 250 MeV. In some implementations, the magnetic field strength may be in the range of 4 T to 20 T and the proton energy may be in the range of 150 to 300 MeV. In some implementations, the magnetic field strength of the active return coils may be in the range of 2.5 T to 12 T.


The radiation therapy system described in this example is used for proton radiation therapy, but the same principles and details can be applied in analogous systems for use in heavy ion (ion) treatment systems.


An example synchrocyclotron includes a magnet system that contains a particle source, a radio frequency (RF) drive system, and a beam extraction system. In some implementations, types of particle accelerators may be used in which one or more of these elements is external to the accelerator.


Referring to FIGS. 4 and 5, the magnetic field established by the magnet system has a shape appropriate to maintain focus of a contained proton beam using a combination of a split pair of annular superconducting coils 400, 401 and a pair of shaped ferromagnetic (e.g., low carbon steel) pole faces 403, 404.


The two superconducting magnet coils are centered on a common axis 405 and are spaced apart along the axis. Referring to FIGS. 6 and 7, the coils may be formed by of Nb3Sn-based superconducting 0.8 mm diameter strands 701 (that initially comprise a niobium-tin core surrounded by a copper sheath) deployed in a twisted cable-in-channel conductor geometry. After seven individual strands are cabled together, they are heated to cause a reaction that forms the final (brittle) superconducting material of the wire. After the material has been reacted, the wires are soldered into the copper channel (outer dimensions 3.18×2.54 mm and inner dimensions 2.08×2.08 mm) and covered with insulation 702 (in this example, a woven fiberglass material). The copper channel containing the wires 703 is then wound in a coil having a rectangular cross-section of 8.55 cm×19.02 cm, having 26 layers and 49 turns per layer. The wound coil is then vacuum impregnated with an epoxy compound. The finished coils 400, 401 are mounted on an annular stainless steel reverse support structure 601. Heater blankets 602 are placed at intervals in the layers of the windings to protect the assembly in the event of a magnet quench.


The geometry of the main coils is maintained by support structure 601, which exerts a restorative force 605 that works against the distorting (e.g., expansion) force produced when the coils are energized. The coil positions may be maintained relative to the magnet pole piece and cryostat using a set of tension links (not shown) that connect the support structure to a cryostat cover (described below) that defines the perimeter of the cryostat.


The main superconducting coils are maintained at temperatures near absolute zero (e.g., about 4 degrees Kelvin) by enclosing the coil assembly (the coils and the support structure) inside an evacuated annular aluminum or stainless steel cryostatic chamber that provides at least some free space around the coil structure. In some implementations, the temperature near absolute zero is achieved and maintained using a cooling channel (not shown) containing liquid helium, which is formed inside the support structure, and which contains a thermal connection between the liquid helium in the channel and the corresponding superconducting coil. An example of a liquid helium cooling system of the type described above, and that may be used is described in U.S. patent application Ser. No. 13/148,000 (Begg et al.).


In FIGS. 4 and 5, the superconducting coils 400, 401 are mounted on the interior of support structure 601. In some implementations, support structure 601 may be made of structural steel, such as stainless steel, or carbon fiber. Active return coils 409, 410 are mounted on the exterior of support structure 601, as shown in FIGS. 4 and 5. A banding ring 411, which may be made, e.g., of carbon fiber or other appropriate material, is mounted around active return coils 409, 410 to hold them in place during magnet operation and thereby maintain their shape (e.g., in response to expansive force resulting from operation). Each active return coil 409, 410 is concentric with respect to its corresponding main coil 400, 401.


The active return coils may be made of superconducting material, such as niobium-titanium or other appropriate materials. The active return coils may be constructed in the same manner as the main coils. In some implementations, the active return coils may be maintained at superconducting temperatures in the same manner as the main superconducting coils, e.g., by conducting heat to a liquid helium cooling channel (not shown in FIGS. 4 and 5). In some implementations, the active return coils may be cooled using other techniques.


Support structure 601, including the main and active return coils, surrounds ferromagnetic (e.g., iron) pole pieces 403, 404, which together define a cavity 412. An ion source is at about the center of cavity 412 to provide the particles for acceleration. In other examples, the ion source may be external to the accelerator. Particles are accelerated in cavity 412 and output as a beam to an extraction channel (not shown) inside the magnet assembly. From the extraction channel, the beam is output essentially directly to the patient.


The support structure, the pole pieces, the main coils and the active return coils (along with other structure, not described herein) are housed in a cryostat cover 415 which, among other things, maintains the temperature of the magnet assembly. Cryostat cover 415 may be may be made of stainless steel, carbon, or other appropriate, relatively lightweight material. Accordingly, as indicated above, in some implementations, a particle accelerator containing the example magnet assembly may have a weight that is less than, or about equal to, one of the following weights: 20 tons, 19 tons, 18 tons, 17 tons, 16 tons, 15 tons, 14 tons, 14 tons, 13 tons, 12 tons, 11 tons, 10 tons, 9 tons, 8 tons, 7 tons, 6 tons, 5 tons, or 4 tons. The actual weight of the particle accelerator and of the magnet assembly may depend on a variety of factors, and is not limited to the example weights provided here.


Examples of particle sources that may be included in cavity 412 are as follows. Referring to FIG. 8, in some implementations, a particle source 800 has a Penning ion gauge geometry. The particle source may be as described below, or the particle source may be of the type described in U.S. patent application Ser. No. 11/948,662 incorporated herein by reference. U.S. patent application Ser. No. 11/948,662 describes a particle source in which a tube containing plasma is interrupted at at least a portion of its mid-plane. The remaining features of the particle source are similar to those described with respect to FIG. 8.


Particle source 800 is fed from a supply of hydrogen through a gas line and a tube that delivers gaseous hydrogen. Electric cables carry an electric current from a current source to stimulate electron discharge from cathodes 804, 805 that are aligned with the magnetic field, 810.


In this example, the discharged electrons ionize the gas exiting through a small hole from tube 811 to create a supply of positive ions (protons) for acceleration by one semicircular (dee-shaped) radio-frequency plate 900 that spans half of the space enclosed by the magnet structure and one dummy dee plate 902. In the case of an interrupted particle source (an example of which is described in U.S. patent application Ser. No. 11/948,662), all (or a substantial part) of the tube containing plasma is removed at the acceleration region, thereby allowing ions to be more rapidly accelerated in a relatively high magnetic field.


As shown in FIG. 9, the dee plate 900 is a hollow metal structure that has two semicircular surfaces 903, 905 that enclose a space 907 in which the protons are accelerated during half of their rotation around the space enclosed by the magnet structure. A duct 909 opening into the space 907 extends through the pole piece to an external location from which a vacuum pump can be attached to evacuate the space 907 and the rest of the space within a vacuum chamber in which the acceleration takes place. The dummy dee 902 comprises a rectangular metal ring that is spaced near to the exposed rim of the dee plate. The dummy dee is grounded to the vacuum chamber and pole piece. The dee plate 900 is driven by a radio-frequency signal that is applied at the end of a radio-frequency transmission line to impart an electric field in the space 907. The radio frequency electric field is made to vary in time as the accelerated particle beam increases in distance from the geometric center. Examples of radio frequency waveform generators that are useful for this purpose are described in U.S. patent application Ser. No. 11/187,633, titled “A Programmable Radio Frequency Waveform Generator for a Synchrocyclotron,” filed Jul. 21, 2005, and in U.S. Provisional Application No. 60/590,089, same title, filed on Jul. 21, 2004, both of which are incorporated herein by reference. The radio frequency electric field may be controlled in the manner described in U.S. patent application Ser. No. 11/948,359, entitled “Matching A Resonant Frequency Of A Resonant Cavity To A Frequency Of An Input Voltage”, the contents of which are incorporated herein by reference.


For the beam emerging from the centrally-located particle source to clear the particle source structure as it begins to spiral outward, a large voltage difference is applied across the radio frequency plates. 20,000 Volts may be applied across the radio frequency plates. In some versions from 8,000 to 20,000 Volts may be applied across the radio frequency plates. To reduce the power required to drive this large voltage, the magnet structure may be arranged to reduce the capacitance between the radio frequency plates and ground. This may be done by forming holes with sufficient clearance from the radio frequency structures through the outer pole piece and the cryostat housing and making sufficient space between the magnet pole faces.


The high voltage alternating potential that drives the dee plate has a frequency that is swept downward during the accelerating cycle to account for the increasing relativistic mass of the protons and the decreasing magnetic field. The dummy dee does not require a hollow semi-cylindrical structure as it is at ground potential along with the vacuum chamber walls. Other plate arrangements could be used, such as more than one pair of accelerating electrodes driven with different electrical phases or multiples of the fundamental frequency. The RF structure can be tuned to keep its Q high during the radio frequency sweep by using, for example, a rotating capacitor having intermeshing rotating and stationary blades. During each meshing of the blades, the capacitance increases, thus lowering the resonant frequency of the RF structure. The blades can be shaped to create a precise frequency sweep required. A drive motor for the rotating condenser can be phase locked to the RF generator for precise control. One bunch of particles is accelerated during each meshing of the blades of the rotating condenser.


The vacuum chamber (e.g., cavity 412) in which the acceleration occurs is a generally cylindrical container that is thinner in the center and thicker at the rim. The vacuum chamber encloses the RF plates and the particle source and is evacuated by the vacuum pump. Maintaining a high vacuum reduces the chances that accelerating ions will be lost to collisions with gas molecules and enables the RF voltage to be kept at a higher level without arcing to ground.


Protons traverse a generally spiral orbital path beginning at the particle source. In half of each loop of the spiral path, the protons gain energy as they pass through the RF electric field in space 907. As the ions gain energy, the radius of the central orbit of each successive loop of their spiral path is larger than the prior loop until the loop radius reaches the maximum radius of the pole face. At that location a magnetic and electric field perturbation directs ions into an area where the magnetic field rapidly decreases, and the ions depart the area of the high magnetic field and are directed through an evacuated tube (which is part of the accelerator), referred to herein as the extraction channel, to exit the pole piece of the cyclotron. A magnetic regenerator may be used to change the magnetic field perturbation to direct the ions. The ions exiting the cyclotron will tend to disperse as they enter the area of markedly decreased magnetic field that exists in the room around the cyclotron. Beam shaping elements in the extraction channel redirect the ions so that they stay in a straight beam of limited spatial extent.


As the beam exits the extraction channel it may be passed through a beam formation system that can be programmably controlled to create a desired combination of scattering angle and range modulation for the beam. Examples of beam forming systems useful for that purpose are described in U.S. patent application Ser. No. 10/949,734, titled “A Programmable Particle Scatterer for Radiation Therapy Beam Formation”, filed Sep. 24, 2004, and U.S. Provisional Application No. 60/590,088, filed Jul. 21, 2005, both of which are incorporated herein by reference. The beam formation system may be used in conjunction with an inner gantry to direct a beam to the patient.


During operation, plates absorb energy from the applied radio frequency field as a result of conductive resistance along the surfaces of the plates. This energy appears as heat and may be removed from the plates using water cooling lines that release the heat in a heat exchanger.


Stray magnetic fields exiting from the cyclotron are limited by active return coils 409, 410. Accordingly, separate magnetic shielding is typically not required. However, in some implementations, a separate magnetic shield may be used. The separate magnetic shield may include a layer ferromagnetic material (e.g., steel or iron) that encloses the cryostat and is separated by a space.


As mentioned, the gantry allows the synchrocyclotron to be rotated about the horizontal rotational axis 332. The gantry is driven to rotate by an electric motor mounted to one or both of the gantry legs and connected to the bearing housings by drive gears. The rotational position of the gantry is derived from signals provided by shaft angle encoders incorporated into the gantry drive motors and the drive gears.


Referring to FIG. 10, at the location at which the ion beam exits synchrocyclotron 302, a beam formation system 1001 acts on the ion beam to give it properties suitable for patient treatment. For example, the beam may be spread and its depth of penetration varied to provide uniform radiation across a given target volume. The beam formation may can include passive scattering elements as well as active scanning elements.


All of the active systems of the synchrocyclotron (current driven superconducting coils, RF-driven plates, vacuum pumps for the vacuum acceleration chamber and for a superconducting coil cooling chamber, current driven particle source, hydrogen gas source, and RF plate coolers, for example), may be controlled by appropriate synchrocyclotron control electronics (not shown), which may include, e.g., one or more computers programmed with appropriate programs (e.g., executable instructions) to effect control.


The control of the gantry, the patient support, the active beam shaping elements, and the synchrocyclotron to perform a therapy session may also be achieved by appropriate therapy control electronics (not shown).


Further details regarding the foregoing system may be found in U.S. Pat. No. 7,728,311, filed on Nov. 16, 2006 and entitled “Charged Particle Radiation Therapy”, and in U.S. patent application Ser. No. 12/275,103, filed on Nov. 20, 2008 and entitled “Inner Gantry”. The contents of U.S. Pat. No. 7,728,311 and in U.S. patent application Ser. No. 12/275,103 are hereby incorporated by reference into this disclosure.


Any two more of the foregoing implementations may be used in an appropriate combination in an appropriate particle accelerator (e.g., a synchrocyclotron). Likewise, individual features of any two more of the foregoing implementations may be used in an appropriate combination.


Elements of different implementations described herein may be combined to form other implementations not specifically set forth above. Elements may be left out of the processes, systems, apparatus, etc., described herein without adversely affecting their operation. Various separate elements may be combined into one or more individual elements to perform the functions described herein.


The example implementations described herein are not limited to use with a particle therapy system or to use with the example particle therapy systems described herein. Rather, the example implementations can be used in any appropriate system that directs accelerated particles to an output.


Additional information concerning the design of the particle accelerator described herein can be found in U.S. Provisional Application No. 60/760,788, entitled “High-Field Superconducting Synchrocyclotron” and filed Jan. 20, 2006; U.S. patent application Ser. No. 11/463,402, entitled “Magnet Structure For Particle Acceleration” and filed Aug. 9, 2006; and U.S. Provisional Application No. 60/850,565, entitled “Cryogenic Vacuum Break Pneumatic Thermal Coupler” and filed Oct. 10, 2006, all of which are incorporated herein by reference as if set forth in full.


The following applications, which were filed on Sep. 28, 2012, are incorporated by reference into the subject application as if set forth herein in full: the U.S. Provisional Application entitled “CONTROLLING INTENSITY OF A PARTICLE BEAM” (Application No. 61/707,466), the U.S. Provisional Application entitled “ADJUSTING ENERGY OF A PARTICLE BEAM” (Application No. 61/707,515), the U.S. Provisional Application entitled “ADJUSTING COIL POSITION” (Application No. 61/707,548), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM USING MAGNETIC FIELD FLUTTER” (Application No. 61/707,572), the U.S. Provisional Application entitled “MAGNETIC FIELD REGENERATOR” (Application No. 61/707,590), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM” (Application No. 61/707,704), the U.S. Provisional Application entitled “CONTROLLING PARTICLE THERAPY (Application No. 61/707,624), and the U.S. Provisional Application entitled “CONTROL SYSTEM FOR A PARTICLE ACCELERATOR” (Application No. 61/707,645).


The following are also incorporated by reference into the subject application as if set forth herein in full: U.S. Pat. No. 7,728,311 which issued on Jun. 1, 2010, U.S. patent application Ser. No. 11/948,359 which was filed on Nov. 30, 2007, U.S. patent application Ser. No. 12/275,103 which was filed on Nov. 20, 2008, U.S. patent application Ser. No. 11/948,662 which was filed on Nov. 30, 2007, U.S. Provisional Application No. 60/991,454 which was filed on Nov. 30, 2007, U.S. Pat. No. 8,003,964 which issued on Aug. 23, 2011, U.S. Pat. No. 7,208,748 which issued on Apr. 24, 2007, U.S. Pat. No. 7,402,963 which issued on Jul. 22, 2008, and U.S. patent application Ser. No. 11/937,573 filed on Nov. 9, 2007.


Any features of the subject application may be combined with one or more appropriate features of the following: the U.S. Provisional Application entitled “CONTROLLING INTENSITY OF A PARTICLE BEAM” (Application No. 61/707,466), the U.S. Provisional Application entitled “ADJUSTING ENERGY OF A PARTICLE BEAM” (Application No. 61/707,515), the U.S. Provisional Application entitled “ADJUSTING COIL POSITION” (Application No. 61/707,548), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM USING MAGNETIC FIELD FLUTTER” (Application No. 61/707,572), the U.S. Provisional Application entitled “MAGNETIC FIELD REGENERATOR” (Application No. 61/707,590), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM” (Application No. 61/707,704), the U.S. Provisional Application entitled “CONTROLLING PARTICLE THERAPY (Application No. 61/707,624), and the U.S. Provisional Application entitled “CONTROL SYSTEM FOR A PARTICLE ACCELERATOR” (Application No. 61/707,645), U.S. Pat. No. 7,728,311 which issued on Jun. 1, 2010, U.S. patent application Ser. No. 11/948,359 which was filed on Nov. 30, 2007, U.S. patent application Ser. No. 12/275,103 which was filed on Nov. 20, 2008, U.S. patent application Ser. No. 11/948,662 which was filed on Nov. 30, 2007, U.S. Provisional Application No. 60/991,454 which was filed on Nov. 30, 2007, U.S. Pat. No. 8,003,964 which issued on Aug. 23, 2011, U.S. Pat. No. 7,208,748 which issued on Apr. 24, 2007, U.S. Pat. No. 7,402,963 which issued on Jul. 22, 2008, U.S. patent application Ser. No. 13/148,000 filed Feb. 9, 2010, and U.S. patent application Ser. No. 11/937,573 filed on Nov. 9, 2007.


Other implementations not specifically described herein are also within the scope of the following claims.

Claims
  • 1. A particle accelerator comprising: a magnet to generate a magnetic field, the magnet comprising first superconducting coils to pass current in a first direction to thereby generate the first magnetic field, the first magnetic field being at least 4 Tesla (T);an active return system comprising second superconducting coils, each of the second superconducting coils surrounding, and being concentric with, a corresponding first superconducting coil, the second superconducting coils for passing current in a second direction that is opposite to the first direction to thereby generate a second magnetic field having a magnetic field of at least 2.5 T, the second magnetic field having a polarity that is opposite to a polarity of the first magnetic field; anda single structure on which at least one first superconducting coil and corresponding second superconducting coil are mounted.
  • 2. The particle accelerator of claim 1, further comprising: a power supply to provide current to both the first superconducting coils and to the second superconducting coils.
  • 3. The particle accelerator of claim 1, wherein the first superconducting coils and the second superconducting coils are all mounted on the single structure.
  • 4. The particle accelerator of claim 3, wherein the first superconducting coils are mounted on an interior of the single structure and the second superconducting coils are mounted on an exterior of the single structure such that the second superconducting coils are separated from the first superconducting coils by at least part of the single structure.
  • 5. The particle accelerator of claim 3, further comprising: a banding ring around at least one of the second superconducting coils.
  • 6. The particle accelerator of claim 3, wherein the single structure comprises at least one of stainless steel and carbon fiber.
  • 7. The particle accelerator of claim 1, further comprising: magnetic pole pieces defining the cavity, the single structure being around at least part of the magnetic pole pieces.
  • 8. The particle accelerator of claim 7, further comprising: a cryostat cover around at least part of the single structure and at least part of the magnetic pole pieces, the cryostat cover comprising a non-ferromagnetic material.
  • 9. The particle accelerator of claim 1, which weighs less than 15 tons.
  • 10. The particle accelerator of claim 1, which weighs less than 10 tons.
  • 11. A proton therapy system comprising: the particle accelerator of claim 1; anda gantry on which the particle accelerator is mounted, the gantry being rotatable relative to a patient position;wherein the proton therapy system is configured to output protons essentially directly from the particle accelerator to the patient position.
  • 12. The proton therapy system of claim 11, wherein the particle accelerator comprises a synchrocyclotron.
  • 13. The proton therapy system of claim 11, wherein the particle accelerator comprises: a particle source to provide ionized plasma to a cavity containing the first magnetic field; anda voltage source to provide voltage to accelerate a beam comprised of pulses of ionized plasma towards an exit.
  • 14. A particle accelerator comprising: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles to produce a particle beam, the cavity having a first magnetic field for causing particles accelerated from the plasma column to move orbitally within the cavity, the RF voltage being controllable to vary in time as the particle beam increases in distance from the plasma column;a magnet to generate the first magnetic field in the cavity, the magnet comprising first superconducting coils to pass current in a first direction to thereby generate the first magnetic field;an active return system comprising second superconducting coils, each of the second superconducting coils surrounding, and being concentric with, a corresponding first superconducting coil, the second superconducting coils for passing current in a second direction that is opposite to the first direction to thereby generate a second magnetic field having a magnetic field of at least 2.5 Tesla (T), the second magnetic field having a polarity that is opposite to a polarity of the first magnetic field; anda single structure on which at least one first superconducting coil and corresponding second superconducting coil are mounted.
  • 15. The particle accelerator of claim 14, wherein the first magnetic field is least 4 T.
  • 16. The particle accelerator of claim 15, wherein the second magnetic field is at between 2.5 T and 12 T.
  • 17. The particle accelerator of claim 14, wherein the first magnetic field is between 4 T and 20 T and the second magnetic field is between 2.5 T and 12 T.
  • 18. The particle accelerator of claim 14, further comprising: a single power supply to provide current to both the first superconducting coils and to the second superconducting coils.
  • 19. The particle accelerator of claim 14, wherein the first superconducting coils and the second superconducting coils are all mounted on the single structure.
  • 20. The particle accelerator of claim 19, wherein the first superconducting coils are mounted on an interior of the single structure and the second superconducting coils are mounted on an exterior of the single structure such that the second superconducting coils are separated from the first superconducting coils by at least part of the single structure.
  • 21. The particle accelerator of claim 19, further comprising: a banding ring around at least one of the second superconducting coils.
  • 22. The particle accelerator of claim 19, wherein the single structure comprises at least one of stainless steel and carbon fiber.
  • 23. The particle accelerator of claim 14, further comprising: magnetic pole pieces defining the cavity, the single structure being around at least part of the magnetic pole pieces.
  • 24. The particle accelerator of claim 23, further comprising: a cryostat cover around at least part of the single structure and at least part of the magnetic pole pieces, the cryostat cover comprising a non-ferromagnetic material.
  • 25. The particle accelerator of claim 14, which weighs less than 15 tons.
  • 26. The particle accelerator of claim 14, which weighs less than 10 tons.
  • 27. A proton therapy system comprising: the particle accelerator of claim 14; anda gantry on which the particle accelerator is mounted, the gantry being rotatable relative to a patient position;wherein the proton therapy system is configured to output protons essentially directly from the particle accelerator to the patient position.
US Referenced Citations (576)
Number Name Date Kind
2280606 Van et al. Apr 1942 A
2492324 Salisbury Dec 1949 A
2615129 McMillan Oct 1952 A
2616042 Weeks Oct 1952 A
2659000 Salisbury Nov 1953 A
2701304 Dickinson Feb 1955 A
2789222 Martin Apr 1957 A
3175131 Burleigh et al. Mar 1965 A
3432721 Naydan et al. Mar 1969 A
3582650 Avery Jun 1971 A
3679899 Dimeff Jul 1972 A
3689847 Verster Sep 1972 A
3757118 Hodge et al. Sep 1973 A
3868522 Bigham et al. Feb 1975 A
3886367 Castle May 1975 A
3925676 Bigham et al. Dec 1975 A
2958327 Marancik et al. May 1976 A
3955089 McIntyre et al. May 1976 A
3958327 Marancik et al. May 1976 A
3992625 Schmidt et al. Nov 1976 A
4038622 Purcell Jul 1977 A
4047068 Ress et al. Sep 1977 A
4112306 Nunan Sep 1978 A
4129784 Tschunt et al. Dec 1978 A
4139777 Rautenbach Feb 1979 A
4197510 Szu Apr 1980 A
4220866 Symmons et al. Sep 1980 A
4230129 LeVeen Oct 1980 A
4256966 Heinz Mar 1981 A
4293772 Stieber Oct 1981 A
4336505 Meyer Jun 1982 A
4342060 Gibson Jul 1982 A
4345210 Tran Aug 1982 A
4353033 Karasawa Oct 1982 A
4425506 Brown et al. Jan 1984 A
4490616 Cipollina et al. Dec 1984 A
4507614 Prono et al. Mar 1985 A
4507616 Blosser et al. Mar 1985 A
4589126 Augustsson et al. May 1986 A
4598208 Brunelli et al. Jul 1986 A
4628523 Heflin Dec 1986 A
4633125 Blosser et al. Dec 1986 A
4641057 Blosser et al. Feb 1987 A
4641104 Blosser et al. Feb 1987 A
4651007 Perusek et al. Mar 1987 A
4680565 Jahnke Jul 1987 A
4705955 Mileikowsky Nov 1987 A
4710722 Jahnke Dec 1987 A
4726046 Nunan Feb 1988 A
4734653 Jahnke Mar 1988 A
4736173 Blosser et al. Apr 1988 A
4737727 Yamada et al. Apr 1988 A
4739173 Blosser et al. Apr 1988 A
4745367 Dustmann et al. May 1988 A
4754147 Maughan et al. Jun 1988 A
4763483 Olsen Aug 1988 A
4767930 Stieber et al. Aug 1988 A
4769623 Marsing et al. Sep 1988 A
4771208 Jongen et al. Sep 1988 A
4783634 Yamamoto et al. Nov 1988 A
4808941 Marsing Feb 1989 A
4812658 Koehler Mar 1989 A
4843333 Marsing et al. Jun 1989 A
4845371 Stieber Jul 1989 A
4865284 Gosis et al. Sep 1989 A
4868843 Nunan Sep 1989 A
4868844 Nunan Sep 1989 A
4870287 Cole et al. Sep 1989 A
4880985 Jones Nov 1989 A
4894541 Ono Jan 1990 A
4896206 Denham Jan 1990 A
4902993 Krevent Feb 1990 A
4904949 Wilson Feb 1990 A
4905267 Miller et al. Feb 1990 A
4917344 Prechter et al. Apr 1990 A
4943781 Wilson et al. Jul 1990 A
4945478 Merickel et al. Jul 1990 A
4968915 Wilson et al. Nov 1990 A
4987309 Klasen et al. Jan 1991 A
4992744 Fujita et al. Feb 1991 A
4996496 Kitamura et al. Feb 1991 A
5006759 Krispel Apr 1991 A
5010562 Hernandez et al. Apr 1991 A
5012111 Ueda Apr 1991 A
5017789 Young et al. May 1991 A
5017882 Finlan May 1991 A
5036290 Sonobe et al. Jul 1991 A
5039057 Prechter et al. Aug 1991 A
5039867 Nishihara et al. Aug 1991 A
5046078 Hernandez et al. Sep 1991 A
5072123 Johnsen Dec 1991 A
5111042 Sullivan et al. May 1992 A
5111173 Matsuda et al. May 1992 A
5117194 Nakanishi et al. May 1992 A
5117212 Yamamoto et al. May 1992 A
5117829 Miller et al. Jun 1992 A
5148032 Hernandez Sep 1992 A
5166531 Huntzinger Nov 1992 A
5189687 Bova et al. Feb 1993 A
5191706 Cosden Mar 1993 A
5240218 Dye Aug 1993 A
5260579 Yasuda et al. Nov 1993 A
5260581 Lesyna et al. Nov 1993 A
5278533 Kawaguchi Jan 1994 A
5285166 Hiramoto et al. Feb 1994 A
5317164 Kurokawa May 1994 A
5336891 Crewe Aug 1994 A
5341104 Anton et al. Aug 1994 A
5349198 Takanaka Sep 1994 A
5365742 Boffito et al. Nov 1994 A
5374913 Pissantezky et al. Dec 1994 A
5382914 Hamm et al. Jan 1995 A
5401973 McKeown et al. Mar 1995 A
5405235 Lebre et al. Apr 1995 A
5434420 McKeown et al. Jul 1995 A
5440133 Moyers et al. Aug 1995 A
5451794 McKeown et al. Sep 1995 A
5461773 Kawaguchi Oct 1995 A
5463291 Carroll et al. Oct 1995 A
5464411 Schulte et al. Nov 1995 A
5492922 Palkowitz Feb 1996 A
5511549 Legg et al. Apr 1996 A
5521469 Laisne May 1996 A
5538942 Koyama et al. Jul 1996 A
5549616 Schulte et al. Aug 1996 A
5561697 Takafuji et al. Oct 1996 A
5585642 Britton et al. Dec 1996 A
5633747 Nikoonahad May 1997 A
5635721 Bardi et al. Jun 1997 A
5668371 Deasy et al. Sep 1997 A
5672878 Yao Sep 1997 A
5691679 Ackermann et al. Nov 1997 A
5726448 Smith et al. Mar 1998 A
5727554 Kalend et al. Mar 1998 A
5730745 Schulte et al. Mar 1998 A
5751781 Brown et al. May 1998 A
5778047 Mansfield et al. Jul 1998 A
5783914 Hiramoto et al. Jul 1998 A
5784431 Kalend et al. Jul 1998 A
5797924 Schulte et al. Aug 1998 A
5811944 Sampayan et al. Sep 1998 A
5818058 Nakanishi et al. Oct 1998 A
5821705 Caporasco et al. Oct 1998 A
5825845 Blair et al. Oct 1998 A
5841237 Alton Nov 1998 A
5846043 Spath Dec 1998 A
5851182 Sahadevan Dec 1998 A
5866912 Slater et al. Feb 1999 A
5874811 Finlan et al. Feb 1999 A
5895926 Britton et al. Apr 1999 A
5920601 Nigg et al. Jul 1999 A
5929458 Nemezawa et al. Jul 1999 A
5963615 Egley et al. Oct 1999 A
5993373 Nonaka et al. Nov 1999 A
6008499 Hiramoto et al. Dec 1999 A
6034377 Pu Mar 2000 A
6057655 Jongen May 2000 A
6061426 Linders et al. May 2000 A
6064807 Arai et al. May 2000 A
6066851 Madono et al. May 2000 A
6080992 Nonaka et al. Jun 2000 A
6087670 Hiramoto et al. Jul 2000 A
6094760 Nonaka et al. Aug 2000 A
6118848 Reiffel Sep 2000 A
6140021 Nakasuji et al. Oct 2000 A
6144875 Sachweikard et al. Nov 2000 A
6158708 Egley et al. Dec 2000 A
6207952 Kan et al. Mar 2001 B1
6219403 Nishihara Apr 2001 B1
6222905 Yoda et al. Apr 2001 B1
6241671 Ritter et al. Jun 2001 B1
6246066 Yuehu Jun 2001 B1
6256591 Yoda et al. Jul 2001 B1
6265837 Akiyama et al. Jul 2001 B1
6268610 Pu Jul 2001 B1
6278239 Caporasco et al. Aug 2001 B1
6279579 Riaziat et al. Aug 2001 B1
6307914 Kunieda et al. Oct 2001 B1
6316776 Hiramoto et al. Nov 2001 B1
6366021 Meddaugh et al. Apr 2002 B1
6369585 Yao Apr 2002 B2
6380545 Yan Apr 2002 B1
6407505 Bertsche Jun 2002 B1
6417634 Bergstrom Jul 2002 B1
6433336 Jongen et al. Aug 2002 B1
6433349 Akiyama et al. Aug 2002 B2
6433494 Kulish et al. Aug 2002 B1
6441569 Janzow Aug 2002 B1
6443349 Van Der Burg Sep 2002 B1
6465957 Whitham et al. Oct 2002 B1
6472834 Hiramoto et al. Oct 2002 B2
6476403 Dolinskii et al. Nov 2002 B1
6492922 New Dec 2002 B1
6493424 Whitham Dec 2002 B2
6498444 Hanna et al. Dec 2002 B1
6501961 Kirkpatrick Dec 2002 B1
6501981 Schweikard et al. Dec 2002 B1
6519316 Collins Feb 2003 B1
6593696 Ding et al. Jul 2003 B2
6594336 Nishizawa et al. Jul 2003 B2
6600164 Badura et al. Jul 2003 B1
6617598 Matsuda Sep 2003 B1
6621889 Mostafavi Sep 2003 B1
6639234 Badura et al. Oct 2003 B1
6646383 Bertsche et al. Nov 2003 B2
6670618 Hartmann et al. Dec 2003 B1
6683318 Haberer et al. Jan 2004 B1
6683426 Kleeven Jan 2004 B1
6693283 Eickhoff et al. Feb 2004 B2
6710362 Kraft et al. Mar 2004 B2
6713773 Lyons et al. Mar 2004 B1
6713976 Zumoto et al. Mar 2004 B1
6717162 Jongen Apr 2004 B1
6736831 Hartmann et al. May 2004 B1
6745072 Badura et al. Jun 2004 B1
6769806 Moyers Aug 2004 B2
6774383 Norimine et al. Aug 2004 B2
6777689 Nelson Aug 2004 B2
6777700 Yanagisawa et al. Aug 2004 B2
6780149 Schulte Aug 2004 B1
6799068 Hartmann et al. Sep 2004 B1
6800866 Amemiya et al. Oct 2004 B2
6803591 Muramatsu et al. Oct 2004 B2
6814694 Pedroni Nov 2004 B1
6822244 Beloussov et al. Nov 2004 B2
6853703 Svatos et al. Feb 2005 B2
6864770 Nemoto et al. Mar 2005 B2
6865254 Nafstadius Mar 2005 B2
6873123 Marchand et al. Mar 2005 B2
6891177 Kraft et al. May 2005 B1
6891924 Yoda et al. May 2005 B1
6894300 Reimoser et al. May 2005 B2
6897451 Kaercher et al. May 2005 B2
6914396 Symons et al. Jul 2005 B1
6936832 Norimine et al. Aug 2005 B2
6953943 Yanagisawa et al. Oct 2005 B2
6965116 Wagner et al. Nov 2005 B1
6969194 Nafstadius Nov 2005 B1
6979832 Yanagisawa et al. Dec 2005 B2
6984835 Harada Jan 2006 B2
6992312 Yanagisawa et al. Jan 2006 B2
6993112 Hesse Jan 2006 B2
7008105 Amann et al. Mar 2006 B2
7011447 Moyers Mar 2006 B2
7012267 Moriyama et al. Mar 2006 B2
7014361 Ein-Gal Mar 2006 B1
7026636 Yanagisawa et al. Apr 2006 B2
7038403 Mastrangeli et al. May 2006 B2
7045781 Adamec et al. May 2006 B2
7049613 Yanagisawa et al. May 2006 B2
7053389 Yanagisawa et al. May 2006 B2
7054801 Sakamoto et al. May 2006 B2
7060997 Norimine et al. Jun 2006 B2
7071479 Yanagisawa et al. Jul 2006 B2
7073508 Moyers Jul 2006 B2
7081619 Bashkirov et al. Jul 2006 B2
7084410 Beloussov et al. Aug 2006 B2
7091478 Haberer Aug 2006 B2
7102144 Matsuda et al. Sep 2006 B2
7122811 Matsuda et al. Oct 2006 B2
7122966 Norling et al. Oct 2006 B2
7122978 Nakanishi et al. Oct 2006 B2
7135678 Wang et al. Nov 2006 B2
7138771 Bechthold et al. Nov 2006 B2
7154107 Yanagisawa et al. Dec 2006 B2
7154108 Tadokoro et al. Dec 2006 B2
7154991 Earnst et al. Dec 2006 B2
7162005 Bjorkholm Jan 2007 B2
7173264 Moriyama et al. Feb 2007 B2
7173265 Miller et al. Feb 2007 B2
7173385 Caporasco et al. Feb 2007 B2
7186991 Kato et al. Mar 2007 B2
7193227 Hiramoto et al. Mar 2007 B2
7199382 Rigney et al. Apr 2007 B2
7208748 Sliski et al. Apr 2007 B2
7212608 Nagamine et al. May 2007 B2
7212609 Nagamine et al. May 2007 B2
7221733 Takai et al. May 2007 B1
7227161 Matsuda et al. Jun 2007 B2
7247869 Tadokoro et al. Jul 2007 B2
7257191 Sommer Aug 2007 B2
7259529 Tanaka Aug 2007 B2
7262424 Moriyama et al. Aug 2007 B2
7262565 Fujisawa Aug 2007 B2
7274018 Adamec et al. Sep 2007 B2
7280633 Cheng et al. Oct 2007 B2
7295649 Johnsen Nov 2007 B2
7297967 Yanagisawa et al. Nov 2007 B2
7301162 Matsuda et al. Nov 2007 B2
7307264 Brusasco et al. Dec 2007 B2
7318805 Schweikard et al. Jan 2008 B2
7319231 Moriyama et al. Jan 2008 B2
7319336 Baur et al. Jan 2008 B2
7331713 Moyers Feb 2008 B2
7332880 Ina et al. Feb 2008 B2
7345291 Kats Mar 2008 B2
7345292 Moriyama et al. Mar 2008 B2
7348557 Armit Mar 2008 B2
7348579 Pedroni Mar 2008 B2
7351988 Naumann et al. Apr 2008 B2
7355189 Yanagisawa et al. Apr 2008 B2
7368740 Beloussov et al. May 2008 B2
7372053 Yamashita et al. May 2008 B2
7378672 Harada May 2008 B2
7381979 Yamashita et al. Jun 2008 B2
7397054 Natori et al. Jul 2008 B2
7397901 Johnsen Jul 2008 B1
7398309 Baumann et al. Jul 2008 B2
7402822 Guertin et al. Jul 2008 B2
7402823 Guertin et al. Jul 2008 B2
7402824 Guertin et al. Jul 2008 B2
7402963 Sliski Jul 2008 B2
7405407 Hiramoto et al. Jul 2008 B2
7425717 Matsuda et al. Sep 2008 B2
7432516 Peggs et al. Oct 2008 B2
7439528 Nishiuchi et al. Oct 2008 B2
7446328 Rigney et al. Nov 2008 B2
7446490 Jongen et al. Nov 2008 B2
7449701 Fujimaki et al. Nov 2008 B2
7453076 Welch et al. Nov 2008 B2
7465944 Ueno et al. Dec 2008 B2
7466085 Nutt Dec 2008 B2
7468506 Rogers et al. Dec 2008 B2
7473913 Hermann et al. Jan 2009 B2
7476867 Fritsch et al. Jan 2009 B2
7476883 Nutt Jan 2009 B2
7482606 Groezinger et al. Jan 2009 B2
7492556 Atkins et al. Feb 2009 B2
7507975 Mohr Mar 2009 B2
7525104 Harada Apr 2009 B2
7541905 Antaya Jun 2009 B2
7547901 Guertin et al. Jun 2009 B2
7554096 Ward et al. Jun 2009 B2
7554097 Ward et al. Jun 2009 B2
7555103 Johnsen Jun 2009 B2
7557358 Ward et al. Jul 2009 B2
7557359 Ward et al. Jul 2009 B2
7557360 Ward et al. Jul 2009 B2
7557361 Ward et al. Jul 2009 B2
7560715 Pedroni Jul 2009 B2
7560717 Matsuda et al. Jul 2009 B2
7567694 Lu et al. Jul 2009 B2
7574251 Lu et al. Aug 2009 B2
7576499 Caporaso et al. Aug 2009 B2
7579603 Birgy et al. Aug 2009 B2
7579610 Grozinger et al. Aug 2009 B2
7582866 Furuhashi et al. Sep 2009 B2
7582885 Katagiri et al. Sep 2009 B2
7582886 Trbojevic Sep 2009 B2
7586112 Chiba et al. Sep 2009 B2
7598497 Yamamoto et al. Oct 2009 B2
7609009 Tanaka et al. Oct 2009 B2
7609809 Kapatoes et al. Oct 2009 B2
7609811 Siljamaki et al. Oct 2009 B1
7615942 Sanders et al. Nov 2009 B2
7629598 Harada Dec 2009 B2
7639853 Olivera et al. Dec 2009 B2
7639854 Schnarr et al. Dec 2009 B2
7643661 Ruchala et al. Jan 2010 B2
7656258 Antaya et al. Feb 2010 B1
7659521 Pedroni Feb 2010 B2
7659528 Uematsu Feb 2010 B2
7668291 Nord et al. Feb 2010 B2
7672429 Urano et al. Mar 2010 B2
7679073 Urano et al. Mar 2010 B2
7682078 Rietzel Mar 2010 B2
7692166 Muraki et al. Apr 2010 B2
7692168 Moriyama et al. Apr 2010 B2
7696499 Miller et al. Apr 2010 B2
7696847 Antaya Apr 2010 B2
7701677 Schultz et al. Apr 2010 B2
7709818 Matsuda et al. May 2010 B2
7710051 Caporaso et al. May 2010 B2
7728311 Gall Jun 2010 B2
7746978 Cheng et al. Jun 2010 B2
7755305 Umezawa et al. Jul 2010 B2
7759642 Nir Jul 2010 B2
7763867 Birgy et al. Jul 2010 B2
7767988 Kaiser et al. Aug 2010 B2
7770231 Prater et al. Aug 2010 B2
7772577 Saito et al. Aug 2010 B2
7773723 Nord et al. Aug 2010 B2
7773788 Lu et al. Aug 2010 B2
7778488 Nord et al. Aug 2010 B2
7783010 Clayton Aug 2010 B2
7784127 Kuro et al. Aug 2010 B2
7786451 Ward et al. Aug 2010 B2
7786452 Ward et al. Aug 2010 B2
7789560 Moyers Sep 2010 B2
7791051 Beloussov et al. Sep 2010 B2
7796731 Nord et al. Sep 2010 B2
7801269 Cravens et al. Sep 2010 B2
7801270 Nord et al. Sep 2010 B2
7801988 Baumann et al. Sep 2010 B2
7807982 Nishiuchi et al. Oct 2010 B2
7809107 Nord et al. Oct 2010 B2
7812319 Diehl et al. Oct 2010 B2
7812326 Grozinger et al. Oct 2010 B2
7816657 Hansmann et al. Oct 2010 B2
7817778 Nord et al. Oct 2010 B2
7817836 Chao et al. Oct 2010 B2
7834334 Grozinger et al. Nov 2010 B2
7834336 Boeh et al. Nov 2010 B2
7835494 Nord et al. Nov 2010 B2
7835502 Spence et al. Nov 2010 B2
7839972 Ruchala et al. Nov 2010 B2
7839973 Nord et al. Nov 2010 B2
7848488 Mansfield Dec 2010 B2
7857756 Warren et al. Dec 2010 B2
7860216 Jongen et al. Dec 2010 B2
7860550 Saracen et al. Dec 2010 B2
7868301 Diehl Jan 2011 B2
7875801 Tsotsis Jan 2011 B2
7875861 Huttenberger et al. Jan 2011 B2
7875868 Moriyama et al. Jan 2011 B2
7881431 Aoi et al. Feb 2011 B2
7894574 Nord et al. Feb 2011 B1
7906769 Blasche et al. Mar 2011 B2
7914734 Livingston Mar 2011 B2
7919765 Timmer Apr 2011 B2
7920040 Antaya et al. Apr 2011 B2
7920675 Lomax et al. Apr 2011 B2
7928415 Bert et al. Apr 2011 B2
7934869 Ivanov et al. May 2011 B2
7940881 Jongen et al. May 2011 B2
7943913 Balakin May 2011 B2
7947969 Pu May 2011 B2
7949096 Cheng et al. May 2011 B2
7950587 Henson et al. May 2011 B2
7960710 Kruip et al. Jun 2011 B2
7961844 Takeda et al. Jun 2011 B2
7977648 Westerly et al. Jul 2011 B2
7977656 Fujimaki et al. Jul 2011 B2
7982198 Nishiuchi et al. Jul 2011 B2
7982416 Tanaka et al. Jul 2011 B2
7984715 Moyers Jul 2011 B2
7986768 Nord et al. Jul 2011 B2
7987053 Schaffner Jul 2011 B2
7989785 Emhofer et al. Aug 2011 B2
7990524 Jureller et al. Aug 2011 B2
7997553 Sloan et al. Aug 2011 B2
8002466 Von Neubeck et al. Aug 2011 B2
8003964 Stark et al. Aug 2011 B2
8009803 Nord et al. Aug 2011 B2
8009804 Siljamaki et al. Aug 2011 B2
8039822 Rietzel Oct 2011 B2
8041006 Boyden et al. Oct 2011 B2
8044364 Yamamoto Oct 2011 B2
8049187 Tachikawa Nov 2011 B2
8053508 Korkut et al. Nov 2011 B2
8053739 Rietzel Nov 2011 B2
8053745 Moore Nov 2011 B2
8053746 Timmer et al. Nov 2011 B2
8067748 Balakin Nov 2011 B2
8069675 Radovinsky et al. Dec 2011 B2
8071966 Kaiser et al. Dec 2011 B2
8080801 Safai Dec 2011 B2
8085899 Nord et al. Dec 2011 B2
8089054 Balakin Jan 2012 B2
8093564 Balakin Jan 2012 B2
8093568 Mackie et al. Jan 2012 B2
8111125 Antaya et al. Feb 2012 B2
8129699 Balakin Mar 2012 B2
8144832 Balakin Mar 2012 B2
8173981 Trbojevic May 2012 B2
8188688 Balakin May 2012 B2
8198607 Balakin Jun 2012 B2
8222613 Tajiri et al. Jul 2012 B2
8227768 Smick et al. Jul 2012 B2
8232536 Harada Jul 2012 B2
8288742 Balakin Oct 2012 B2
8291717 Radovinsky et al. Oct 2012 B2
8294127 Tachibana Oct 2012 B2
8304725 Komuro et al. Nov 2012 B2
8304750 Preikszas et al. Nov 2012 B2
8309941 Balakin Nov 2012 B2
8330132 Guertin et al. Dec 2012 B2
8334520 Otaka et al. Dec 2012 B2
8335397 Takane et al. Dec 2012 B2
8344340 Gall et al. Jan 2013 B2
8350214 Otaki et al. Jan 2013 B2
8368038 Balakin Feb 2013 B2
8368043 Havelange et al. Feb 2013 B2
8373143 Balakin Feb 2013 B2
8373145 Balakin Feb 2013 B2
8378299 Frosien Feb 2013 B2
8378321 Balakin Feb 2013 B2
8382943 Clark Feb 2013 B2
8389949 Harada et al. Mar 2013 B2
8399866 Balakin Mar 2013 B2
8405042 Honda et al. Mar 2013 B2
8405056 Amaldi et al. Mar 2013 B2
8415643 Balakin Apr 2013 B2
8416918 Nord et al. Apr 2013 B2
8421041 Balakin Apr 2013 B2
8426833 Trbojevic Apr 2013 B2
8436323 Iseki et al. May 2013 B2
8440987 Stephani et al. May 2013 B2
8445872 Behrens et al. May 2013 B2
8466441 Iwata et al. Jun 2013 B2
8472583 Star-Lack et al. Jun 2013 B2
8483357 Siljamaki et al. Jul 2013 B2
8487278 Balakin Jul 2013 B2
8552406 Phaneuf et al. Oct 2013 B2
8552408 Hanawa et al. Oct 2013 B2
8569717 Balakin Oct 2013 B2
8581215 Balakin Nov 2013 B2
8581523 Gall et al. Nov 2013 B2
8581525 Antaya et al. Nov 2013 B2
20020172317 Maksimchuk et al. Nov 2002 A1
20030048080 Amemiya et al. Mar 2003 A1
20030125622 Schweikard et al. Jul 2003 A1
20030136924 Kraft et al. Jul 2003 A1
20030152197 Moyers Aug 2003 A1
20030163015 Yanagisawa et al. Aug 2003 A1
20030183779 Norimine et al. Oct 2003 A1
20030234369 Glukhoy Dec 2003 A1
20040000650 Yanagisawa et al. Jan 2004 A1
20040017888 Seppi et al. Jan 2004 A1
20040056212 Yanagisawa et al. Mar 2004 A1
20040061077 Muramatsu et al. Apr 2004 A1
20040061078 Muramatsu et al. Apr 2004 A1
20040085023 Chistyakov May 2004 A1
20040098445 Baumann et al. May 2004 A1
20040111134 Muramatsu et al. Jun 2004 A1
20040118081 Reimoser et al. Jun 2004 A1
20040149934 Yanagisawa et al. Aug 2004 A1
20040159795 Kaercher et al. Aug 2004 A1
20040173763 Moriyama et al. Sep 2004 A1
20040174958 Moriyama et al. Sep 2004 A1
20040183033 Moriyama et al. Sep 2004 A1
20040183035 Yanagisawa et al. Sep 2004 A1
20040200982 Moriyama et al. Oct 2004 A1
20040200983 Fujimaki et al. Oct 2004 A1
20040213381 Harada Oct 2004 A1
20040227104 Matsuda et al. Nov 2004 A1
20040232356 Norimine et al. Nov 2004 A1
20040240626 Moyers Dec 2004 A1
20050058245 Ein-Gal Mar 2005 A1
20050089141 Brown Apr 2005 A1
20050161618 Eros Jul 2005 A1
20050184686 Caporaso et al. Aug 2005 A1
20050228255 Saracen et al. Oct 2005 A1
20050234327 Saracen et al. Oct 2005 A1
20050247890 Norimine et al. Nov 2005 A1
20060017015 Sliski et al. Jan 2006 A1
20060067468 Rietzel Mar 2006 A1
20060126792 Li Jun 2006 A1
20060145088 Ma Jul 2006 A1
20060284562 Hruby et al. Dec 2006 A1
20070001128 Sliski et al. Jan 2007 A1
20070013273 Albert et al. Jan 2007 A1
20070014654 Haverfield et al. Jan 2007 A1
20070023699 Yamashita et al. Feb 2007 A1
20070029510 Hermann et al. Feb 2007 A1
20070051904 Kaiser et al. Mar 2007 A1
20070092812 Caporaso et al. Apr 2007 A1
20070114945 Mattaboni et al. May 2007 A1
20070121926 Le Gall et al. May 2007 A1
20070145916 Caporaso et al. Jun 2007 A1
20070171015 Antaya Jul 2007 A1
20070181519 Khoshnevis Aug 2007 A1
20070284548 Kaiser et al. Dec 2007 A1
20080093567 Gall Apr 2008 A1
20080218102 Sliski Sep 2008 A1
20090096179 Stark et al. Apr 2009 A1
20090140671 O'Neal et al. Jun 2009 A1
20090140672 Gall et al. Jun 2009 A1
20090200483 Gall et al. Aug 2009 A1
20100045213 Sliski et al. Feb 2010 A1
20100230617 Gall Sep 2010 A1
20120142538 Antaya et al. Jun 2012 A1
20130009571 Antaya Jan 2013 A1
20130053616 Gall et al. Feb 2013 A1
20140028220 Bromberg et al. Jan 2014 A1
20140042934 Tsutsui Feb 2014 A1
Foreign Referenced Citations (127)
Number Date Country
2629333 May 2007 CA
1537657 Oct 2004 CN
101932361 Dec 2010 CN
101933405 Dec 2010 CN
101933406 Dec 2010 CN
101061759 May 2011 CN
2753397 Jun 1978 DE
31 48 100 Jun 1983 DE
35 30 446 Aug 1984 DE
41 01 094 May 1992 DE
4411171 Oct 1995 DE
0 194 728 Sep 1986 EP
0 277 521 Aug 1988 EP
0 208 163 Jan 1989 EP
0 222 786 Jul 1990 EP
0 221 987 Jan 1991 EP
0 499 253 Aug 1992 EP
0 306 966 Apr 1995 EP
0 388 123 May 1995 EP
0 465 597 May 1997 EP
0 911 064 Jun 1998 EP
0 864 337 Sep 1998 EP
0 776 595 Dec 1998 EP
1 069 809 Jan 2001 EP
1 153 398 Apr 2001 EP
1 294 445 Mar 2003 EP
1 348 465 Oct 2003 EP
1 358 908 Nov 2003 EP
1 371 390 Dec 2003 EP
1 402 923 Mar 2004 EP
1 430 932 Jun 2004 EP
1 454 653 Sep 2004 EP
1 454 654 Sep 2004 EP
1 454 655 Sep 2004 EP
1 454 656 Sep 2004 EP
1 454 657 Sep 2004 EP
1 477 206 Nov 2004 EP
1 738 798 Jan 2007 EP
1 826 778 Aug 2007 EP
1 949 404 Jul 2008 EP
2227295 Sep 2010 EP
2232961 Sep 2010 EP
2232962 Sep 2010 EP
2227295 May 2011 EP
1 605 742 Jun 2011 EP
2363170 Sep 2011 EP
2363171 Sep 2011 EP
2 560 421 Aug 1985 FR
2911843 Aug 2008 FR
0 957 342 May 1964 GB
2 015 821 Sep 1979 GB
2 361 523 Oct 2001 GB
43-23267 Oct 1968 JP
57-162527 Oct 1982 JP
58-141000 Aug 1983 JP
61-80800 Apr 1986 JP
62-150804 Jul 1987 JP
62-186500 Aug 1987 JP
10-071213 Mar 1988 JP
63-149344 Jun 1988 JP
63-218200 Sep 1988 JP
63-226899 Sep 1988 JP
64-89621 Apr 1989 JP
01-276797 Nov 1989 JP
01-302700 Dec 1989 JP
4-94198 Mar 1992 JP
04-128717 Apr 1992 JP
04-129768 Apr 1992 JP
04-273409 Sep 1992 JP
04-337300 Nov 1992 JP
05-341352 Dec 1993 JP
06-233831 Aug 1994 JP
06-036893 Oct 1994 JP
07-260939 Oct 1995 JP
07-263196 Oct 1995 JP
08-173890 Jul 1996 JP
08-264298 Oct 1996 JP
09-162585 Jun 1997 JP
11-47287 Feb 1999 JP
11-102800 Apr 1999 JP
11-243295 Sep 1999 JP
2000-294399 Oct 2000 JP
2001-6900 Jan 2001 JP
2001-129103 May 2001 JP
2002-164686 Jun 2002 JP
2003-517755 May 2003 JP
05-046928 Mar 2008 JP
2008-507826 Mar 2008 JP
2009-515671 Apr 2009 JP
2009-516905 Apr 2009 JP
2011-505191 Feb 2011 JP
2011-505670 Feb 2011 JP
2011-507151 Mar 2011 JP
300137 Nov 1969 SU
569 635 Aug 1977 SU
200930160 Jul 2009 TW
200934682 Aug 2009 TW
200939908 Sep 2009 TW
200940120 Oct 2009 TW
WO 8607229 Dec 1986 WO
WO 90012413 Oct 1990 WO
WO 9203028 Feb 1992 WO
WO 9302536 Feb 1993 WO
WO 9817342 Apr 1998 WO
WO 9939385 Aug 1999 WO
WO 0040064 Jul 2000 WO
WO 0049624 Aug 2000 WO
WO 0126230 Apr 2001 WO
WO 0126569 Apr 2001 WO
WO 0207817 Jan 2002 WO
WO 03039212 May 2003 WO
WO 03092812 Nov 2003 WO
WO 2004026401 Apr 2004 WO
WO 2004101070 Nov 2004 WO
WO 2006-012467 Feb 2006 WO
WO 2007061937 May 2007 WO
WO 2007084701 Jul 2007 WO
WO 2007130164 Nov 2007 WO
WO 2007145906 Dec 2007 WO
WO 2008030911 Mar 2008 WO
WO 2008081480 Oct 2008 WO
WO 2009048745 Apr 2009 WO
WO 2009070173 Jun 2009 WO
WO 2009070588 Jun 2009 WO
WO 2009073480 Jun 2009 WO
WO2014018706 Jan 2014 WO
WO2014018876 Jan 2014 WO
Non-Patent Literature Citations (267)
Entry
“Beam Delivery and Properties,” Journal of the ICRU, 2007, 7(2):20 pages.
“510(k) Summary: Ion Beam Applications S.A.”, FDA, Jul. 12, 2001, 5 pages.
“510(k) Summary: Optivus Proton Beam Therapy System”, Jul. 21, 2000, 5 pages.
“An Accelerated Collaboration Meets with Beaming Success,” Lawrence Livermore National Laboratory, Apr. 12, 2006, S&TR, Livermore, California, pp. 1-3, http://www.llnl.gov/str/April06/Caporaso.html.
“CPAC Highlights Its Proton Therapy Program at ESTRO Annual Meeting”, TomoTherapy Incorporated, Sep. 18, 2008, Madison, Wisconsin, pp. 1-2.
“Indiana's mega-million proton therapy cancer center welcomes its first patients” [online] Press release, Health & Medicine Week, 2004, retrieved from NewsRx.com, Mar. 1, 2004, pp. 119-120.
“LLNL, UC Davis Team Up to Fight Cancer,”Lawrence Livermore National Laboratory, Apr. 28, 2006, SF-06-04-02, Livermore, California, pp. 1-4.
“Patent Assignee Search Paul Scherrer Institute,” Library Services at Fish & Richardson P.C., Mar. 20, 2007, 40 pages.
“Patent Prior Art Search for ‘Proton Therapy System’,” Library Services at Fish & Richardson P.C., Mar. 20, 2007, 46 pages.
“Superconducting Cyclotron Contract” awarded by Paul Scherrer Institute (PSI), Villigen, Switzerland, http://www.accel.de/News/superconducting—cyclotron—contract.htm, Jan. 2009, 1 page.
“The Davis 76-Inch Isochronous Cyclotron”, Beam On: Crocker Nuclear Laboratory, University of California, 2009, 1 page.
“The K100 Neutron-therapy Cyclotron,” National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/tech/accelerators/k100, Feb. 2005, 1 page.
“The K250 Proton therapy Cyclotron,” National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/tech/accelerators/k250.html, Feb. 2005, 2 pages.
“The K250 Proton-therapy Cyclotron Photo Illustration,” National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/media/image/experimental-equipment-technology/250.html, Feb. 2005, 2 pages.
18th Japan Conference on Radiation and Radioisotopes [Japanese], Nov. 25-27, 1987, 9 pages.
Abrosimov et al., “1000MeV Proton Beam Therapy facility at Petersburg Nuclear Physics Institute Synchrocyclotron,” Medical Radiology (Moscow) 32, 10 (1987) revised in Journal of Physics, Conference Series 41, 2006, pp. 424-432, Institute of Physics Publishing Limited.
Abrosimov et al., Proc. Academy Science, 1985, USSR 5, p. 84.
Adachi et al., “A 150MeV FFAG Synchrotron with “Return-Yoke Free” Magent,” Proceedings of the 2001 Particle Accelerator Conference, Chicago, 2001, 3 pages.
Ageyev et al., “The IHEP Accelerating and Storage Complex (UNK) Status Report,” 11th International Conference on High-Energy Accelerators, 1980, pp. 60-70.
Agosteo et al., “Maze Design of a gantry room for proton therapy,” Nuclear Instruments & Methods In Physics Research, 1996, Section A, 382, pp. 573-582.
Alexeev et al., “R4 Design of Superconducting Magents for Proton Synchrotrons,” Proceedings of the Fifth International Cryogenic Engineering Conference, 1974, pp. 531-533.
Allardyce et al., “Performance and Prospects of the Reconstructed CERN 600 MeV Synchrocyclotron,” IEEE Transactions on Nuclear Science USA, Jun. 1977, ns-24:(3)1631-1633.
Alonso, “Magnetically Scanned Ion Beams for Radiation Therapy,” Accelerator & Fusion Research Division, Lawrence Berkeley Laboratory, Berkeley, CA, Oct. 1988, 13 pages.
Amaldi et al., “The Italian project for a hadrontherapy centre” Nuclear Instruments and Methods in Physics Research A, 1995, 360, pp. 297-301.
Amaldi, “Overview of the world landscape of Hadrontherapy and the projects of the TERA foundation,” Physica Medica, An International journal Devoted to the Applications of Physics to Medicine and Biology, Jul. 1998, vol. XIV, Supplement 1, 6th Workshop on Heavy Charged Particles in Biology and Medicine, Instituto Scientific Europeo (ISE), Sep. 29-Oct. 1, 1977, Baveno, pp. 76-85.
Anferov et al., “Status of the Midwest Proton Radiotherapy Institute,” Proceedings of the 2003 Particle Accelerator Conference, 2003, pp. 699-701.
Anferov et al., “The Indiana University Midwest Proton Radiation Institute,” Proceedings of the 2001 Particle Accelerator Conference, 2001, Chicago, pp. 645-647.
Appun, “Various problems of magnet fabrication for high-energy accelerators,” Journal for All Engineers Interested in the Nuclear Field, 1967, pp. 10-16 (1967) [Lang.: German], English bibliographic information (http://www.osti.gov/energycitations/product.biblio.jsp?osti—id=4442292).
Arduini et al. “Physical specifications of clinical proton beams from a synchrotron,” Med. Phys, Jun. 1996, 23 (6): 939-951.
Badano et al., “Proton-Ion Medical Machine Study (PIMMS) Part I,” PIMMS, Jan. 1999, 238 pages.
Beeckman et al., “Preliminary design of a reduced cost proton therapy facility using a compact, high field isochronous cyclotron,” Nuclear Instruments and Methods in Physics Reasearch B56/57, 1991, pp. 1201-1204.
Bellomo et al., “The Superconducting Cyclotron Program at Michigan State University,” Bulletin of the American Physical Society, Sep. 1980, 25(7):767.
Benedikt and Carli, “Matching to Gantries for Medical Synchrotrons” IEEE Proceedings of the 1997 Particle Accelerator Conference, 1997, pp. 1379-1381.
Bieth et al., “A Very Compact Protontherapy Facility Based on an Extensive Use of High Temperature Superconductors (HTS)” Cyclotrons and their Applications 1998, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Caen, Jun. 14-19, 1998, pp. 669-672.
Bigham, “Magnetic Trim Rods for Superconducting Cyclotrons,” Nuclear Instruments and Methods (North-Holland Publishing Co.), 1975, 141:223-228.
Bimbot, “First Studies of the Extemal Beam from the Orsay S.C. 200 MeV,” Institut de Physique Nucleaire, BP 1, Orsay, France, IEEE, 1979, pp. 1923-1926.
Blackmore et al., “Operation of the Triumf Proton Therapy Facility,” IEEE Proceedings of the 1997 Particle Accelerator Conferenc, May 12-16, 1997 3:3831-3833.
Bloch, “The Midwest Proton Therapy Center,” Application of Accelerators in Research and Industry, Proceedings of the Fourteenth Int'l Conf., Part Two, Nov. 1996, pp. 1253-1255.
Blosser et al., “Problems and Accomplishments of Superconducting Cyclotrons,” Proceedings of the 14th International Conference, Cyclotrons and Their Applications, Oct. 1995, pp. 674-684.
Blosser et al., “Superconducting Cyclotrons”, Seventh International Conference on Cyclotrons and their Applications, Aug. 19-22, 1975, pp. 584-594.
Blosser et al., “Progress toward an experiment to study the effect of RF grounding in an internal ion source on axial oscillations of the beam in a cyclotron,” National Superconducting Cyclotron Laboratory, Michigan State University, Report MSUCL-760, CP600, Cyclotrons and their Applications 2011, Sixteenth International Conference, 2001, pp. 274-276.
Blosser et al., “A Compact Superconducting Cyclotron for the Production of High Intensity Protons,” Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, 1:1054-1056.
Blosser et al., “Advances in Superconducting Cyclotrons at Michigan State University,” Proceedings of the 11th International Conference on Cyclotrons and their Applications, Oct. 1986, pp. 157-167, Tokyo.
Blosser et al., “Characteristics of a 400 (Q2/A) MeV Super-Conducting Heavy-Ion Cyclotron,” Bulletin of the American Physical Society, Oct. 1974, p. 1026.
Blosser et al., “Medical Accelerator Projects at Michigan State Univ.” IEEE Proceedings of the 1989 Particle Accelerator Conference, Mar. 20-23, 1989, 2:742-746.
Blosser et al., “Superconducting Cyclotron for Medical Application”, IEEE Transactions on Magnetics, Mar. 1989, 25(2): 1746-1754.
Blosser, “Application of Superconductivity in Cyclotron Construction,” Ninth International Conference on Cyclotrons and their Applications, Sep. 1981, pp. 147-157.
Blosser, “Applications of Superconducting Cyclotrons,” Twelfth International Conference on Cyclotrons and Their Applications, May 8-12, 1989, pp. 137-144.
Blosser, “Future Cyclotrons,” AIP, The Sixth International Cyclotron Conference, 1972, pp. 16-32.
Blosser, “Medical Cyclotrons,” Physics Today, Special Issue Physical Review Centenary, Oct. 1993, pp. 70-73.
Blosser, “Preliminary Design Study Exploring Building Features Required for a Proton Therapy Facility for the Ontario Cancer Institute”, Mar. 1991, MSUCL-760a, 53 pages.
Blosser, “Program on the Coupled Superconducting Cyclotron Project,” Bulletin of the American Physical Society, Apr. 1981, 26(4):558.
Blosser, “Synchrocyclotron Improvement Programs,” IEEE Transactions on Nuclear Science USA, Jun. 1969, 16(3):Part I, pp. 405-414.
Blosser, “The Michigan State University Superconducting Cyclotron Program,” Nuclear Science, Apr. 1979, NS-26(2):2040-2047.
Blosser, National Superconducting Cyclotron Laboratory, Michigan State University, Report MSUCL-760, 2001, 3 pages.
Blosser, H., Present and Future Superconducting Cyclotrons, Bulletin of the American Physical Society, Feb. 1987, 32(2):171 Particle Accelerator Conference, Washington, D.C.
Blosser, H.G., “Superconducting Cyclotrons at Michigan State University”, Nuclear Instruments & Methods in Physics Research, 1987, vol. B 24/25, part II, pp. 752-756.
Botha et al., “A New Multidisciplinary Separated-Sector Cyclotron Facility,” IEEE Transactions on Nuclear Science, 1977, NS-24(3):1118-1120.
Canadian Office action issued in Canadian application No. 2,629,333 issued Aug. 30, 2010, 5 pages.
Chichili et al., “Fabrication of Nb3Sn Shell-Type Coils with Pre-Preg Ceramic Insulation,” American Institute of Physics Conference Proceedings, AIP USA, No. 711, (XP-002436709, ISSN: 0094-243X), 2004, pp. 450-457.
Chinese Office action from corresponding Chinese application No. 200880125832.9, mailed Jun. 5, 2012, 6 pages.
Chinese Office Action issued in Chinese Application No. 200780102281.X, dated Dec. 7, 2011, 23 pages (with English translation).
Chinese Office action issued in Chinese application No. 200880125832.9, dated Sep. 22, 2011, 111 pages.
Chinese Office action issued in Chinese application No. 200880125918.1, dated Sep. 15, 2011, 111 pages.
Chong et al., Radiology Clinic North American 7, 3319, 1969, 27 pages.
Chu et al., “Performance Specifications for Proton Medical Facility,” Lawrence Berkeley Laboratory, University of California, Mar. 1993, 128 pages.
Chu et al., “Instrumentation for Treatment of Cancer Using Proton and Light-ion Beams,” Review of Scientific Instruments, Aug. 1993, 64 (8):2055-2122.
Chu, “Instrumentation in Medical Systems,” Accelerator and Fusion Research Division, Lawrence Berkeley Laboratory, University of California, Berkeley, CA, May 1995, 9 pages.
Cole et al., “Design and Application of a Proton Therapy Accelerator,” Fermi National Accelerator Laboratory, IEEE, 1985, 5 pages.
Collins, et al., “The Indiana University Proton Therapy System,” Proceedings of EPAC 2006, Edinburgh, Scotland, 2006, 3 pages.
Conradi et al., “Proposed New Facilities for Proton Therapy at iThemba Labs,” Proceedings of EPAC, 2002, pp. 560-562.
C/E Source of Ions for Use in Sychro-Cyclotrons Search, Jan. 31, 2005, 9 pages.
Source Search “Cites of U.S. and Foreign Patents/Published applications in the name of Mitsubishi Denki Kabushiki Kaisha and Containing the Keywords (Proton and Synchrocyclotron),” Jan. 2005, 8 pages.
Cosgrove et aI., “Microdosimetric Studies on the Orsay Proton Synchrocyclotron at 73 and 200 MeV,” Radiation Protection Dosimetry, 1997, 70(1-4):493-496.
Coupland, “High-field (5 T) pulsed superconducting dipole magnet,” Proceedings of the Institution of Electrical Engineers, Jul. 1974, 121(7):771-778.
Coutrakon et al. “Proton Synchrotrons for Cancer Therapy,” Application of Accelerators in Research and Industry—Sixteenth International Conf., American Institute of Physics, Nov. 1-5, 2000, vol. 576, pp. 861-864.
Coutrakon et al., “A prototype beam delivery system for the proton medical accelerator at Loma Linda,” Medical Physics, Nov./Dec. 1991, 18(6):1093-1099.
Cuttone, “Applications of a Particle Accelerators in Medical Physics,” Istituto Nazionale di Fisica Nucleare-Laboratori Nazionali del Sud, V.S. Sofia, 44 Cantania, Italy, Jan. 2010, 17 pages.
Dahl P, “Superconducting Magnet System,” American Institute of Physics, AIP Conference Proceedings, 1987-1988, 2: 1329-1376.
Dialog Search, Jan. 31, 2005, 17 pages.
Dugan et al., “Tevatron Status” IEEE, Particle Accelerator Conference, Accelerator Science & Technology, 1989, pp. 426-430.
Eickhoff et al., “The Proposed Accelerator Facility for Light Ion Cancer Therapy in Heidelberg,” Proceedings of the 1999 Particle Accelerator Conference, New York, 1999, pp. 2513-2515.
Enchevich et al., “Minimizing Phase Losses in the 680 MeV Synchrocyclotron by Correcting the Accelerating Voltage Amplitude,” Atomnaya Energiya, 1969, 26:(3):315-316.
Endo et al., “Compact Proton and Carbon Ion Synchrotrons for Radiation Therapy,” Proceedings of EPAC 2002, Paris France, 2002, pp. 2733-2735.
European Communication issued in corresponding European application No. 11165422.4, dated Sep. 2, 2011, 5 pages.
European Communication issued in European application No. 07868958.5, dated Nov. 26, 2010, 50 pages.
European Patent Office communication issued in European application No. 08856764.9, dated Jul. 30, 2010, 2 pages.
European Patent Office communicationissued in European application No. 07868958.5, dated Jul. 16, 2010, 2 pages.
European Search Report issued in European Application No. 11165423.2, dated Aug. 8, 2011, 118 pages.
Flanz et al., “Treating Patients with the NPTC Accelerator Based Proton Treatment Facility,” Proceedings of the 2003 Particle Accelerator Conference, 2003, pp. 690-693.
Flanz et al., “Large Medical Gantries,” Particle Accelerator Conference, Massachusetts General Hospital, 1995, pp. 1-5.
Flanz et al., “Operation of a Cyclotron Based Proton Therapy Facility”, Massachusetts General Hospital, Boston, MA 02114, pp. 1-4, retrieved from Internet in 2009.
Flanz et al., “The Northeast Proton Therapy Center at Massachusetts General Hospital,” Fifth Workshop on Heavy Charge Particles in Biology and Medicine, GSI, Darmstadt, Aug. 1995, 11 pages.
Flanz, et al., “Scanning Beam Technologies”, PTCOG 2008, 28 pages.
Flood and Frazier,. “The Wide-Band Driven RF System for the Berkeley 88-Inch Cyclotron,” American Institute of Physics, Conference Proceedings., No. 9, 1972, 459-466.
Foster and Kashikhin, “Superconducting Superferric Dipole Magent with Cold Iron Core for the VLHC,” IEEE Transactions on Applied Superconductivity, Mar. 2002, 12(1):111-115.
Friesel et al., “Design and Construction Progress on the IUCF Midwest Proton Radiation Institute,” Proceedings of EPAC 2002, 2002, pp. 2736-2738.
Fukumoto et al., “A Proton Therapy Facility Plan” Cyclotrons and their Applications, Proceedings of the 13th International Conference, Vancouver, Canada, Jul. 6-10, 1992, pp. 258-261.
Fukumoto, “Cyclotron Versus Synchrotron for Proton Beam Therapy,” KEK Prepr., No. 95-122, 995, pp. 533-536.
Goto et al., “Progress on the Sector Magnets for the Riken SRC,” American Institute of Physics, CP600, Cyclotrons and Their Applications 2001, Sixteenth International Conference, 2001, pp. 319-323.
Graffman et al., “Design Studies for a 200 MeV Proton Clinic for Radiotherapy,” AIP Conference Proceedings: Cyclotrons—1972, 1972, No. 9, pp. 603-615.
Graffman et al., Acta Radiol. Therapy Phys. Biol. 1970, 9, 1 (1970).
Graffman, et. al. “Proton radiotherapy with the Uppsala cyclotron. Experience and plans” Strahlentherapie, 1985, 161(12):764-770.
Hede, “Research Groups Promoting Proton Therapy “Lite,”” Journal of the National Cancer Institute, Dec. 6, 2006, 98(23):1682-1684.
Heinz, “Superconducting Pulsed Magnetic Systems for High-Energy Synchrotrons,” Proceedings of the Fourth International Cryogenic Engineering Conference, May 24-26, 1972, pp. 55-63.
Hentschel et al., “Plans for the German National Neutron Therapy Centre with a Hospital-Based 70 MeV Proton Cyclotron at University Hospital Essen/Germany,” Cyclotrons and their Applications, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Caen, Franco, Jun. 14-19, 1998, pp. 21-23.
Hepburn et al., “Superconducting Cyclotron Neutron Source for Therapy,” International Journal of Radiation Oncology Biology Physics, vol. 3 complete, 1977, pp. 387-391.
Hirabayashi, “Development of Superconducting Magnets for Beam Lines and Accelerator at KEK,” IEEE Transaction on Magnetics, Jan. 1981, Mag-17(1):728-731.
International Preliminary Report on Patentability issued in PCT Application No. PCT/US2008/084695, dated Jun. 10, 2010, 10 pages.
International Preliminary Report on Patentability issued in PCT Application No. PCT/US2008/084699, dated Jun. 10, 2010, 8 pages.
International Preliminary Report on Patentability issued in PCT Application No. PCT/US2007/086109, dated Jun. 10, 2010, 7 pages.
International Preliminary Report on Patentability in Internation Application No. PCT/US2006/44853, dated May 29, 2008, 8 pages.
International Preliminary Report on Patentability in Internation Application No. PCT/US2007/001506, dated Jul. 5, 2007, 15 pages.
International Preliminary Report on Patentability in Internation Application No. PCT/US2007/001628, dated Apr. 22, 2008, 15 pages.
International Search Report and Written Opinion in International Application No. PCT/US2006/44853, dated Oct. 5, 2007, 3 pages.
International Search Report and Written Opinion in International Application No. PCT/US2007/001506, dated Jul. 5, 2007, Publication No. WO2007/084701, Published Jul. 26, 2007, 14 pages.
International Preliminary Report on Patentability on International Application No. PCT/US2008/077513, dated Apr. 22, 2010.
International Search Report and Written Opinion in International Application No. PCT/US2008/077513, dated Oct. 1, 2009, 73 pages.
International Search Report and Written Opinion in International Application No. PCT/US2008/084695, dated Jan. 26, 2009, 15 pages.
International Search Report in International Application No. PCT/US2007/001628, dated Feb. 18, 2008, 4 pages.
International Search Report and Written Opinion in International Application No. PCT/US2007/086109, dated Aug. 26, 2008, 6 pages.
International Search Report and Written Opinion in International Application No. PCT/US2008/084699, dated Feb. 4, 2009, 11 pages.
Ishibashi and McInturff, “Winding Design Study of Superconducting 10 T Dipoles for a Synchrotron,” IEEE Transactions on Magnetics, May 1983, MAG-19(3):1364-1367.
Ishibashi and McInturff, “Stress Analysis of Superconducting 10T Magnets for Synchrotron,” Proceedings of the Ninth International Cryogenic Engineering Conference, May 11-14, 1982, pp. 513-516.
Jahnke et al., “First Superconducting Prototype Magnets for a Compact Synchrotron Radiation Source in Operation,” IEEE Transactions on Magnetics, Mar. 1988, 24(2):1230-1232.
Jones and Dershem, “Synchrotron Radiation from Proton in a 20 TEV, 10 TESLA Superconducting Super Collide,r” Proceedings of the 12th International Conference on High-Energy Accelerator, Aug. 11-16, 1983, pp. 138-140.
Jones and Mills, “The South African National Accelerator Centre: Particle Therapy and Isotope Production Programmes,” Radiation Physics and Chemistry, Apr.-Jun. 1998, 51(4-6):571-578.
Jones et al., “Status Report of the NAC Particle Therapy Programme,” Stralentherapie und Onkologie, vol. 175, Suppl. II, Jun. 1999, pp. 30-32.
Jones, “Progress with the 200 MeV Cyclotron Facility at the National Accelerator Centre,” Commission of the European Communities Radiation Protection Proceedings, Fifth Symposium on Neutron Dosimetry, Sep. 17-21, 1984, vol. II, pp. 989-998.
Jones, “Present Status and Future Trends of Heavy Particle Radiotherapy,” Cyclotrons and their Applications 1998, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Jun. 14-19, 1998, pp. 13-20.
Jongen et al., “Development of a Low-cost Compact Cyclotron System for Proton Therapy,” National Institute of Radiol Sci, 1991, No. 81, pp. 189-200.
Jongen et al., “Progress report on the IBA-SHI small cyclotron for cancer therapy” Nuclear Instruments and Methods in Physics Research, Section B, vol. 79, issue 1-4, 1993, pp. 885-889.
Jongent et al., “The proton therapy system for the NPTC: Equipment Description and progress report,” Nuclear Instruments and methods in physics research, 1996, Section B, 113(1): 522-525.
Jongen et al., “The proton therapy system for MGH's NPTC: equipment description and progress report,” Bulletin du Cancer/Radiotherapie, Proceedings of the meeting of the European Heavy Particle Therapy Group, 1996, 83(Suppl. 1):219-222.
Kanai et al., “Three-dimensional Beam Scanning for Proton Therapy,” Nuclear Instruments and Methods in Physic Research, Sep. 1, 1983, The Netherlands, 214(23):491-496.
Karlin et al., “Medical Radiology” (Moscow), 1983, 28, 13.
Karlin et al., “The State and Prospects in the Development of the Medical Proton Tract on the Synchrocyclotron in Gatchina,” Med. Radiol., Moscow, 28(3):28-32 (Mar. 1983)(German with English Abstract on end of p. 32).
Kats and Druzhinin, “Comparison of Methods for Irradiation Prone Patients,” Atomic Energy, Feb. 2003, 94(2):120-123.
Kats and Onosovskii, “A Simple, Compact, Flat System for the Irradiation of a Lying Patient with a Proton Beam from Different Directions,” Instruments and Experimental Techniques, 1996, 39(1): 132-134.
Kats and Onosovskii, “A Planar Magnetooptical System for the Irradiation of a Lying Patient with a Proton Beam from Various Directions,” Instruments and Experimental Techniques, 1996, 39(1):127-131.
Khoroshkov et al.,“Moscow Hospital-Based Proton Therapy Facility Design,” Am. Journal Clinical Oncology: CCT, Apr. 1994, 17(2):109-114.
Kim and Blosser, “Optimized Magnet for a 250 MeV Proton Radiotherapy Cyclotron,” Cyclotrons and Their Applications 2001, May 2001, Sixteenth International Conference, pp. 345-347.
Kim and Yun, “A Light-Ion Superconducting Cyclotron System for Multi-Disciplinary Users,” Journal of the Korean Physical Society, Sep. 2003, 43(3):325-331.
Kim et al., “Construction of 8T Magnet Test Stand for Cyclotron Studies,” IEEE Transactions on Applied Superconductivity, Mar. 1993, 3(1):266-268.
Kim et al., “Design Study of a Superconducting Cyclotron for Heavy Ion Therapy,” Cyclotrons and Their Applications 2001, Sixteenth International Conference, May 13-17, 2001, pp. 324-326.
Kim et al., “Trim Coil System for the Riken Cyclotron Ring Cyclotron,” Proceedings of the 1997 Particle Accelerator Conference, IEEE, Dec. 1981, vol. 3, pp. 214-235 OR 3422-3424, 1998.
Kim, “An Eight Tesla Superconducting Magnet for Cyclotron Studies,” Ph.D. Dissertation, Michigan State University, Department of Physics and Astronomy, 1994, 138 pages.
Kimstrand, “Beam Modelling for Treatment Planning of Scanned Proton Beams,” Digital Comprehensive Summaries of Uppsala dissertations from the Faculty of Medicine 330, Uppsala Universitet, 2008, 58 pages.
Kishida and Yano, “Beam Transport System for the RIKEN SSC (II),” Scientific Papers of the Institute of Physical and Chemical Research, Dec. 1981, 75(4):214-235.
Koehler et al., “Range Modulators for Protons and Heavy Ions,” Nuclear Instruments and Methods, 1975, vol. 131, pp. 437-440.
Koto and Tsujii, “Future of Particle Therapy,” Japanese Journal of Cancer Clinics, 2001, 47(1):95-98 [Lang.: Japanese], English abstract (http://sciencelinks.jp/j-east/article/200206/000020020601A0511453.php).
Kraft et al., “Hadrontherapy in Oncology,” U. Amaldi and Lamson, editors Elsevier Science, 1994, 390 pages.
Krevet et al., “Design of a Strongly Curved Superconducting Bending Magnet for a Compact Synchrotron Light Source,” Advances in Cryogenic Engineering, 1988, vol. 33, pp. 25-32.
Laisne et aI., “The Orsay 200 MeV Synchrocyclotron,” IEEE Transactions on Nuclear Science, Apr. 1979, NS-26(2):1919-1922.
Larsson et al., Nature, 1958, 182:1222.
Larsson, “Biomedical Program for the Converted 200-MeV Synchrocyclotron at the Gustaf Werner Institute,” Radiation Research, 1985, 104:S310-S318.
Lawrence et al., “Heavy particles in acromegaly and Cushing's Disease,” in Endocrine and Norendocrine Hormone Producing Tumors (Year Book Medical Chicago, 1973, pp. 29-61.
Lawrence et al., “Successful Treatment of Acromegaly: Metabolic and Clinical Studies in 145 Patients,” The Journal of Clinical Endrocrinology and Metabolism, Aug. 1970, 31(2), 21 pages.
Lawrence et al., “Treatment of Pituitary Tumors,” (Excerpta medica, Amsterdam/American Elsevier, New York, 1973, pp. 253-262.
Lawrence, Cancer, 1957, 10:795.
Lecroy et al., “Viewing Probe for High Voltage Pulses,” Review of Scientific Instruments USA, Dec. 1960, 31(12):1354.
Lin et al., “Principles and 10 Year Experience of the Beam Monitor System at the PSI Scanned Proton Therapy Facility”, Center for Proton Radiation Therapy, Paul Scherrer Institute, CH-5232, Villigen PSI, Switzerland, 2007, 21 pages.
Linfoot et al., “Acromegaly,” in Hormonal Proteins and Peptides, edited by C.H. Li, 1975, pp. 191-246.
Literature Author and Keyword Search, Feb. 14, 2005, 44 pages.
Literature Keyword Search, Jan. 24, 2005, 96 pages.
Literature Search and Keyword Search for Synchrocyclotron, Jan. 25, 2005, 68 pages.
Literature Search by Company Name/Component Source, Jan. 24, 2005, 111 pages.
Literature Search, Jan. 26, 2005, 36 pages.
Livingston et al., “A capillary ion source for the cyclotron,” Review Science Instruments, Feb. 1939, 10:63.
Mandrillon, “High Energy Medical Accelerators,” EPAC 90, 2nd European Particle Accelerator Conference, Jun. 12-16, 1990, 2:54-58.
Marchand et aI., “1EA Proton Pencil Beam Scanning: an Innovative Solution for Cancer Treatment,” Proceedings of EPAC 2000, Vienna, Austria, 3 pages.
Marti et al., “High Intensity Operation of a Superconducting Cyclotron,” Proceedings of the 14the International Conference, Cyclotrons and Their Applications, Oct. 1995, pp. 45-48 (Oct. 1995).
Martin, “Operational Experience with Superconducting Synchrotron Magnets” Proceedings of the 1987 IEEE Particle Accelerator Conference, Mar. 16-19, 1987, vol. 3 of 3:1379-1382.
Meote et al., “ETOILE Hadrontherapy Project, Review of Design Studies” Proceedings of EPAC 2002, 2002, pp. 2745-2747.
Miyamoto et al., “Development of the Proton Therapy System,” The Hitachi Hyoron, 79(10):775-779 (1997) [Lang: Japanese], English abstract (http://www.hitachi.com/rev/1998/revfeb98/rev4706.htm).
Montelius et al., “The Narrow Proton Beam Therapy Unit at the Svedberg Laboratory in Uppsala,” ACTA Oncologica, 1991, 30:739-745.
Moser et al., “Nonlinear Beam Optics with Real Fields in Compact Storage Rings,” Nuclear Instruments & Methods in Physics Research/Section B, B30, Feb. 1988, No. 1, pp. 105-109.
Moyers et al., “A Continuously Variable Thickness Scatterer for Proton Beams Using Self-compensating Dual Linear Wedges” Lorna Linda University Medical Center, Dept. of Radiation Medicine, Lorna Linda, CA, Nov. 2, 1992, 21 pages.
National Cancer Institute Funding (Senate-Sep. 21, 1992) (www.thomas.loc.gov/cgi-bin/query/z?r102:S21SE2-712 (2 pages).
Nicholson, “Applications of Proton Beam Therapy,” Journal of the American Society of Radiologic Technologists, May/Jun. 1996, 67(5): 439-441.
Nolen et al., “The Integrated Cryogenic—Superconducting Beam Transport System Planned for MSU,” Proceedings of the 12th International Conference on High-Energy Accelerators, Aug. 1983, pp. 549-551.
Norimine et al., “A Design of a Rotating Gantry with Easy Steering for Proton Therapy,” Proceedings of EPAC 2002, 2002, pp. 2751-2753.
Ogino, Takashi, “Heavy Charged Particle Radiotherapy-Proton Beam”, Division of Radiation Oncology, National Cancer Hospital East, Kashiwa, Japan, Dec. 2003, 7 pages.
Okumura et al., “Overview and Future Prospect of Proton Radiotherapy,” Japanese Journal of Cancer Clinics, 1997, 43(2):209-214 [Lang.: Japanese].
Okumura et al., “Proton Radiotherapy” Japanese Journal of Cancer and Chemotherapy, 1993, 10.20(14):2149-2155[Lang.: Japanese].
Outstanding from Search Reports, “Accelerator of Polarized Portons at Fermilab,” 2005, 20 pages.
Paganetti et al., “Proton Beam Radiotherapy—The State of the Art,” Springer Verlag, Heidelberg, ISBN 3-540-00321-5, Oct. 2005, 36 pages.
Palmer and Tollestrup, “Superconducting Magnet Technology for Accelerators,” Annual Review of Nuclear and Particle Science, 1984, vol. 34, pp. 247-284.
Patent Assignee and Keyword Searches for Synchrocyclotron, Jan. 25, 2005, 77 pages.
Pavlovic, “Beam-optics study of the gantry beam delivery system for light-ion cancer therapy,” Nuclear Instruments and Methods in Physics Research, Section A, Nov. 1997, 399(2):439-454(16).
Pedroni and Enge, “Beam optics design of compact gantry for proton therapy” Medical & Biological Engineering & Computing, May 1995, 33(3):271-277.
Pedroni and Jermann,. “SGSMP: Bulletin Mar. 2002 Proscan Project, Progress Report on the PROSCAN Project of PSI” [online] retrieved from www.sgsmp.ch/protA23.htm, Mar. 2002, 5 pages.
Pedroni et al., “A Novel Gantry for Proton Therapy at the Paul Scherrer Institute,” Cycloctrons and Their Applications 2001: Sixteenth International Conference. AIP Conference Proceedings, 2001, 600:13-17.
Pedroni et al., “The 200-MeV proton therapy project at the Paul Scherrer Institute: Conceptual design and practical realization,” Medical Physics, Jan. 1995, 22(1):37-53.
Pedroni, “Accelerators for Charged Particle Therapy: Performance Criteria from the User Point of View,” Cyclotrons and their Applications, Proceedings of the 13th International Conference, Jul. 6-10, 1992, pp. 226-233.
Pedroni, “Latest Developments in Proton Therapy” Proceedings of EPAC 2000, 2000, pp. 240-244.
Pedroni, “Status of Proton Therapy: results and future trends,” Paul Scherrer Institute, Division of Radiation Medicine, 1994, 5 pages.
Peggs et al., “A Survey of Hadron Therapy Accelerator Technologies,” Particle Accelerator Conference, Jun. 25-29, 2007, 7 pages.
Potts et al., “MPWP6-Therapy III: Treatment Aids and Techniques” Medical Physics, Sep./Oct. 1988, 15(5):798.
Pourrahimi et al., “Powder Metallurgy Processed Nb3Sn(Ta) Wire for High Field NMR magnets,” IEEE Transactions on Applied Superconductivity, Jun. 1995, 5(2):1603-1606.
Prieels et al., “The IBA State-of-the-Art Proton Therapy System, Performances and Recent Results,” Application of Accelerators in Research and industry—Sixteenth Int'l. Conf., American Institute of Physics, Nov. 1-5, 2000, 576:857-860.
Rabin et al., “Compact Designs for Comprehensive Proton Beam Clinical Facilities,” Nuclear Instruments & Methods in Physics Research, Apr. 1989, Section B, vol. 40-41, Part II, pp. 1335-1339.
Research & Development Magazine, “Proton Therapy Center Nearing Completion,” Aug. 1999, 41(9):2 pages, (www.rdmag.com).
Resmini, “Design Characteristics of the K=800 Superconducting Cyclotron at M.S.U.,” Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, IEEE Transaction on Nuclear Science, vol. NS-26, No. 2, Apr. 1979, 8 pages.
RetroSearch “Berkeley 88-Inch Cyclotron ‘RF’ or ‘Frequency Control’,” Jan. 21, 2005, 36 pages.
RetroSearch “Berkeley 88-Inch Cyclotron,” Jan. 24, 2005, 170 pages.
RetroSearch “Bernard Gottschalk, Cyclotron, Beams, Compensated Upstream Modulator, Compensated Scatter,” Jan. 21, 2005, 20 pages.
RetroSearch “Cyclotron with ‘RF’ or ‘Frequency Control’,” Jan. 21, 2005, 49 pages.
RetroSearch Gottschalk, Bernard, Harvard Cyclotron Wheel, Jan. 21, 2005, 20 pages.
RetroSearch “Loma Linda University Beam Compensation,” Jan. 21, 2005, 60 pages.
RetroSearch “Loma Linda University, Beam Compensation Foil Wedge,” Jan. 21, 2005, 15 pages.
Revised Patent Keyword Search, Jan. 25, 2005, 88 pages.
Rifuggiato et, al., “Status Report of the LNS Superconducting Cyclotron” Nukleonika, 2003, 48: S131-S134, Supplement 2.
Rode, “Tevatron Cryogenic System,” Proceedings of the 12th International Conference on High-energy Accelerators, Fermilab, Aug. 11-16, 1983, pp. 529-535.
Salzburger et al., “Superconducting Synchrotron Magnets Supraleitende Synchrotronmagnete,” Siemens A.G., Erlangen (West Germany). Abteilung Technische Physik, Report No. BMFT-FB-T-75-25, Oct. 1975, p. 147, Journal Announcement: GRAI7619; STAR1415, Subm-Sponsored by Bundesmin. Fuer Forsch. U. Technol. In German; English Summary.
Schillo et al,. “Compact Superconducting 250 MeV Proton Cyclotron for the PSI Proscan Proton Therapy Project,” Cyclotrons and Their Applications 2001, Sixteenth International Conference, 2001, pp. 37-39.
Schneider et al., “Nevis Synchrocyclotron Conversion Program—RF System,” IEEE Transactions on Nuclear Science USA, Jun. 1969, ns. 16(3): 430-433.
Schneider et al., “Superconducting Cyclotrons,” IEEE Transactions on Magnetics, vol. MAG-11, No. 2, Mar. 1975, New York, pp. 443-446.
Schreuder et al., “The Non-orthogonal Fixed Beam Arrangement for the Second Proton Therapy Facility at the National Accelerator Centre,” Application of Accelerators in Research and Industry, American Institute of Physics, Proceedings of the Fifteenth International Conference, Nov. 1998, Part Two, pp. 963-966.
Schreuder, “Recent Developments in Superconducting Cyclotrons,” Proceedings of the 1995 Particle Accelerator Conference, May 1-5, 1995, vol. 1, pp. 317-321.
Schubert and Blosser, “Conceptual Design of a High Field Ultra-Compact Cyclotron for Nuclear Physics Research,” Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, vol. 1, pp. 1060-1062.
Schubert, “Extending the Feasibility Boundary of the Isochronous Cyclotron,” Dissertation submitted to Michigan State University, 1997, Abstract http://adsabs.harvard.edu/abs/1998PhDT . . . 147S.
Shelaev et al., “Design Features of a Model Superconducting Synchrotron of JINR,” Proceedings of the 12th International Conference on High-energy Accelerators, Aug. 11-16, 1983, pp. 416-418.
Shintomi et. Al, “Technology and Materials for the Superconducting Super Collider (SSC) Project,” [Lang.: Japanese], The Iron and Steel Institute of Japan 00211575, 78(8): 1305-1313, 1992, http://ci.nii.ac.jp/naid/110001493249/en/.
Sisterson, “World Wide Proton Therapy Experience in 1997,” The American Insitute of Physics, Applications of Accelerators in Research and Industry, Proceedings of the Fifteenth International Conference, Part Two, Nov. 1998, pp. 959-962.
Sisterson, “Clinical use of proton and ion beams from a world-wide perspective,” Nuclear Instruments and Methods in Physics Research, Section B, 1989, 40-41:1350-1353.
Slater et al., “Developing a Clinical Proton Accelerator Facility: Consortium-Assisted Technology Transfer,” Conference Record of the 1991 IEEE Particle Accelerator Conference: Accelerator Science and Technology, vol. 1, May 6-9, 1991, pp. 532-536.
Slater et al., “Development of a Hospital-Based Proton Beam Treatment Center,” International Journal of Radiation Oncology Biology Physics, Apr. 1988, 14(4):761-775.
Smith et al., “The Northeast Proton Therapy Center at Massachusetts General Hospital” Journal of Brachytherapy International, Jan. 1997, pp. 137-139.
Snyder and Marti, “Central region design studies for a proposed 250 MeV proton cyclotron,” Nuclear Instruments and Methods in Physics Research, Section A, 1995, vol. 355, pp. 618-623.
Soga, “Progress of Particle Therapy in Japan,” Application of Accelerators in Research and Industry, American Institute of Physics, Sixteenth International Conference, Nov. 2000, pp. 869-872.
Spiller et al., “The GSI Synchrotron Facility Proposal for Acceleration of High Intensity Ion and Proton Beams” Proceedings of the 2003 Particle Accelerator Conference, May 12-16, 2003, vol. 1, pp. 589-591.
Stanford et al., “Method of Temperature Control in Microwave Ferroelectric Measurements,” Sperry Microwave Electronics Company, Clearwater, Florida, Sep. 19, 1960, 1 page.
Tadashi et al., “Large superconducting super collider (SSC) in the planning and materials technology,” 1992, 78(8):1305-1313, The Iron and Steel Institute of Japan 00211575.
Takada, “Conceptual Design of a Proton Rotating Gantry for Cancer Therapy,” Japanese Journal of Medical Physics, 1995, 15(4):270-284.
Takayama et al., “Compact Cyclotron for Proton Therapy,” Proceedings of the 8th Symposium on Accelerator Science and Technology, Japan, Nov. 25-27, 1991, pp. 380-382.
Teng, “The Fermilab Tevatron,” Coral Gables 1981, Proceedings, Gauge Theories, Massive Neutrinos, and Proton Decay, 1981, pp. 43-62.
The Journal of Practical Pharmacy, 1995, 46(1):97-103 [Japanese].
Tilly et al., “Development and verification of the pulsed scanned proton beam at The Svedberg Laboratory in Uppsala,” Phys. Med. Biol., 2007, 52:2741-2754.
Tobias et al., Cancer Research, 1958, 18, 121 (1958).
Tom, “The Use of Compact Cyclotrons for Producing Fast Neutrons for Therapy in a Rotatable Isocentric Gantry,” IEEE Transaction on Nuclear Science, Apr. 1979, 26(2):2294-2298.
Toyoda, “Proton Therapy System”, Sumitomo Heavy Industries, Ltd., 2000, 5 pages.
Trinks et. al., “The Tritron: A Superconducting Separated-Orbit Cyclotron,” Nuclear Instruments and Methods in Physics Research, Section A, 1986, vol. 244, pp. 273-282.
Tsuji, “The Future and Progress of Proton Beam Radiotherapy,” Journal of Japanese Society for Therapeutic Radiology and Oncology, 1994, 6(2):63-76.
UC Davis School of Medicine, “Unlikely Partners Turn Military Defense into Cancer Offense”, Current Issue Summer 2008, Sacramento, California, pp. 1-2.
Umegaki et al., “Development of an Advanced Proton Beam Therapy System for Cancer Treatment” Hitachi Hyoron, 2003, 85(9):605-608 [Lang.: Japanese], English abstract, http://www.hitachi.com/ICSFiles/afieldfile/2004/06/01/r2003—04—104.pdf or http://www.hitachi.com/rev/archive/2003/2005649—12606.html (full text) [Hitachi, 52(4), Dec. 2003].
Umezawa et al., “Beam Commissioning of the new Proton Therapy System for University of Tsukuba,” Proceedings of the 2001 Particle Accelerator Conference, vol. 1, Jun. 18-22, 2001, pp. 648-650.
van Steenbergen, “Superconducting Synchroton Development at BNL,” Proceedings of the 8th International Conference on High-Energy Accelerators CERN 1971, 1971, pp. 196-198.
van Steenbergen, “The CMS, a Cold Magnet Synchrotron to Upgrade the Proton Energy Range of the BNL Facility,” IEEE Transactions on Nuclear Science, Jun. 1971, 18(3):694-698.
Vandeplassche et al., “235 MeV Cyclotron for MGH's Northeast Proton Therapy Center (NPTC): Present Status,” EPAC 96, Fifth European Partical Accelerator Conference, vol. 3, Jun. 10-14, 1996, pp. 2650-2652.
Vorobiev et al., “Concepts of a Compact Achromatic Proton Gantry with a Wide Scanning Field”, Nuclear Instruments and Methods in Physics Research, Section A., 1998, 406(2):307-310.
Vrenken et al., “A Design of a Compact Gantry for Proton Therapy with 2D-Scanning,” Nuclear Instruments and Methods in Physics Research, Section A, 1999, 426(2):618-624.
Wikipedia, “Cyclotron” http://en.wikipedia.org/wiki/Cyclotron (originally visited Oct. 6, 2005, revisited Jan. 28, 2009), 7 pages.
Wikipedia, “Synchrotron” http://en.wikipedia.org/wiki/Synchrotron (originally visited Oct. 6, revisited Jan. 28, 2009), 7 pages.
Worldwide Patent Assignee Search, Jan. 24, 2005, 224 pages.
Worldwide Patent Keyword Search, Jan. 24, 2005, 94 pages.
Written Opinion in PCT Application No. PCT/US2007/001628, dated Feb. 18, 2008, 11 pages.
Wu, “Conceptual Design and Orbit Dynamics in a 250 MeV Superconducting Synchrocyclotron,” Ph.D. Dissertation, Michigan State University, Department of Physics and Astronomy, 1990, 172 pages.
York et al., “Present Status and Future Possibilities at NSCL-MSU,” EPAC 94, Fourth European Particle Accelerator Conference, pp. 554-556, Jun. 1994.
York et al., “The NSCL Coupled Cyclotron Project—Overview and Status,”Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Jun. 1998, pp. 687-691.
Yudelev et al., “Hospital Based Superconducting Cyclotron for Neutron Therapy: Medical Physics Perspective,” Cyclotrons and their applications 2001, 16th International Conference. American Institute of Physics Conference Proceedings, vol. 600, May 13-17, 2001, pp. 40-43.
Zherbin et al., “Proton Beam Therapy at the Leningrad Synchrocyclotron (Clinicomethodological Aspects and Therapeutic Results)”, Aug. 1987, 32(8):17-22, (German with English abstract on pp. 21-22).
U.S. Appl. No. 13/949,459, filed Jul. 24, 2013.
U.S. Appl. No. 13/830,792, filed Mar. 14, 2013.
U.S. Appl. No. 61/676,377, filed Jul. 27, 2012.
U.S. Appl. No. 13/949,450, filed Jul. 24, 2013.
U.S. Appl. No. 13/838,792, filed Mar. 14, 2013.